

(19) World Intellectual Property Organization
International Bureau




(43) International Publication Date
7 September 2001 (07.09.2001)

PCT

(10) International Publication Number
WO 01/64656 A1

- (51) International Patent Classification⁷: **C07D 239/48, 403/12** **Stuart, Eric** [GB/GB]; Alderley Park, Macclesfield, Cheshire SK10 4TG (GB).
- (21) International Application Number: **PCT/GB01/00829** (74) Agent: **BRYANT, Tracey**; AstraZeneca, Global Intellectual Property, P.O. Box 272, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4GR (GB).
- (22) International Filing Date: 26 February 2001 (26.02.2001)
- (25) Filing Language: English (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (26) Publication Language: English (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- (30) Priority Data: 0004887.6 1 March 2000 (01.03.2000) GB
- (71) Applicant (*for all designated States except MG, US*): **ASTRAZENECA AB** [SE/SE]; S-151 85 Sodertälje (SE).
- (71) Applicant (*for MG only*): **ASTRAZENECA UK LIMITED** [GB/GB]; 15 Stanhope Gate, London W1Y 6LN (GB).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): **PEASE, Elizabeth, Janet** [GB/GB]; Alderley Park, Macclesfield, Cheshire SK10 4TG (GB). **WILLIAMS, Emma, Jane** [GB/GB]; Alderley Park, Macclesfield, Cheshire SK10 4TG (GB). **BRADBURY, Robert, Hugh** [GB/GB]; Alderley Park, Macclesfield, Cheshire SK10 4TG (GB). **PEARSON,**
- Published:
— with international search report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: 2,4-DI(HTERO-)ARYLAMINO(-OXY)-5-SUBSTITUTED PYRIMIDINES AS ANTINEOPLASTIC AGENTS



(I)

(57) Abstract: Pyrimidine derivatives of formula (I) wherein Q₁, Q₂, G and R¹ are as defined within; and pharmaceutically acceptable salts and *in vivo* hydrolysable esters thereof are described. Processes for their manufacture, pharmaceutical compositions and their use as cyclin-dependent serine/threonine kinase (CDK) and focal adhesion kinase (FAK) inhibitors are also described.

WO 01/64656 A1

BEST AVAILABLE COPY

2,4-DI (HETERO-) ARYLAMINO (-OXY) -5-SUBSTITUTED PYRIMIDINES AS ANTINEOPLASTIC AGENTS

The invention relates to pyrimidine derivatives, or pharmaceutically acceptable salts or *in vivo* hydrolysable esters thereof, which possess cell-cycle inhibitory activity and are accordingly useful for their anti-cancer (such as anti-cell-proliferative, anti-cell migration and/or apoptotic) activity and are therefore useful in methods of treatment of a warm-blooded animal, such as man. The invention also relates to processes for the manufacture of said pyrimidine derivatives, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments or use in the production of an anti-cancer (anti-cell-proliferation/migration and/or apoptotic) effect in a warm-blooded animal such as man.

A family of intracellular proteins called cyclins play a central role in the cell cycle. The synthesis and degradation of cyclins is tightly controlled such that their level of expression fluctuates during the cell cycle. Cyclins bind to cyclin-dependent serine/threonine kinases (CDKs) and this association is essential for CDK (such as CDK1, CDK2, CDK4 and/or CDK6) activity within the cell. Although the precise details of how each of these factors combine to regulate CDK activity is poorly understood, the balance between the two dictates whether or not the cell will progress through the cell cycle.

The recent convergence of oncogene and tumour suppresser gene research has identified regulation of entry into the cell cycle as a key control point of mitogenesis in tumours. Moreover, CDKs appear to be downstream of a number of oncogene signalling pathways. Disregulation of CDK activity by upregulation of cyclins and/or deletion of endogenous inhibitors appears to be an important axis between mitogenic signalling pathways and proliferation of tumour cells.


Accordingly it has been recognised that an inhibitor of cell cycle kinases, particularly inhibitors of CDK2, CDK4 and/or CDK6 (which operate at the S-phase, G1-S and G1-S phase respectively) should be of value as a selective inhibitor of cell proliferation, such as growth of mammalian cancer cells.

Furthermore, it is believed that inhibition of focal adhesion kinase (FAK), which is involved in signal transduction pathways, induces apoptosis (cell-death) and/or inhibits cell migration and an inhibitor of FAK may therefore have value as an anti-cancer agent.

The present invention is based on the discovery that certain 2,4-pyrimidine compounds surprisingly inhibit the effects of cell cycle kinases showing selectivity for CDK2, CDK4 and CDK6, and also inhibit FAK and thus possess anti-cancer (anti-cell-migration/proliferation and/or apoptotic) properties. Such properties are expected to be of value in the treatment of

5 disease states associated with aberrant cell cycles and cell proliferation such as cancers (solid tumours and leukemias), fibroproliferative and differentiative disorders, psoriasis, rheumatoid arthritis, Kaposi's sarcoma, haemangioma, acute and chronic nephropathies, atheroma, atherosclerosis, arterial restenosis, autoimmune diseases, acute and chronic inflammation, bone diseases and ocular diseases with retinal vessel proliferation.

10 According to the invention there is provided a pyrimidine derivative of the formula (I):



(I)

wherein:

15 Q₁ and Q₂ are independently selected from aryl or carbon linked heteroaryl; and one of Q₁ and Q₂ or both of Q₁ and Q₂ is substituted on a ring carbon by one substituent selected from *N*-(C₁₋₂alkyl)amino, *N,N*-di-(C₁₋₂alkyl)amino, phenyl, heterocyclic group, phenoxy, heterocyclic group-O-, substituted C₁₋₂alkyl, substituted C₁₋₂alkoxy, substituted C₁₋₂alkoxycarbonyl, substituted *N*-(C₁₋₂alkyl)amino, substituted C₁₋₂alkoxyC₁₋₂alkyl,

20 substituted C₂₋₄alkenyl and substituted C₂₋₄alkynyl; wherein said substituents for C₁₋₂alkyl, C₁₋₂alkoxy, C₁₋₂alkoxycarbonyl, *N*-(C₁₋₂alkyl)amino, C₁₋₂alkoxyC₁₋₂alkyl, C₂₋₄alkenyl and C₂₋₄alkynyl are selected from halo, hydroxy, mercapto, nitro, formyl, formamido, carboxy, cyano, amino, ureido, carbamoyl, sulphamoyl, C₁₋₄alkanoyl, C₁₋₄alkoxycarbonyl, phenyl, heterocyclic group, benzoyl, heterocyclic group-C(O)-, C₁₋₄alkylS(O)_a wherein a is 0 to 2,

25 *N'*-(C₁₋₄alkyl)ureido, *N',N'*-di-(C₁₋₄alkyl)ureido, *N'*-(C₁₋₄alkyl)-*N*-(C₁₋₄alkyl)ureido, *N',N'*-di-(C₁₋₄alkyl)-*N*-(C₁₋₄alkyl)ureido, *N*-C₁₋₄alkylamino, *N,N*-di-(C₁₋₄alkyl)amino, *N*-(C₁₋₄alkyl)sulphamoyl, *N,N*-di-(C₁₋₄alkyl)sulphamoyl, *N*-C₁₋₄alkylcarbamoyl,

N,N-di-(C₁₋₄alkyl)carbamoyl and C₁₋₄alkanoylamino; wherein any phenyl, benzyl, benzoyl or heterocyclic group is optionally substituted on a ring carbon by one or more groups selected from R^a; and wherein if any heterocyclic group contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R^b;

5 **G** is -O- or -NR²-;

R² is selected from hydrogen, C₁₋₆alkyl, C₃₋₆alkenyl and C₃₋₆alkynyl; wherein said C₁₋₆alkyl, C₃₋₆alkenyl and C₃₋₆alkynyl are optionally substituted by one or more groups selected from R^c;

R¹ is selected from hydrogen, halo, hydroxy, nitro, amino, *N*-(C₁₋₃alkyl)amino, *N,N*-di-(C₁₋₃alkyl)amino, cyano, trifluoromethyl, trichloromethyl, C₁₋₃alkyl [optionally substituted by 1 or 2 substituents independently selected from halo, cyano, amino, *N*-(C₁₋₃alkyl)amino, *N,N*-di-(C₁₋₃alkyl)amino, hydroxy and trifluoromethyl], C₃₋₅alkenyl [optionally substituted by up to three halo substituents, or by one trifluoromethyl substituent], C₃₋₅alkynyl, C₁₋₃alkoxy, mercapto, C₁₋₃alkylsulphanyl, carboxy and C₁₋₃alkoxycarbonyl;

15 **Q₁** is optionally substituted on a ring carbon by one to four substituents independently selected from halo, mercapto, nitro, formyl, formamido, carboxy, cyano, amino, ureido, carbamoyl, sulphamoyl, C₁₋₄alkyl, C₂₋₄alkenyl, C₂₋₄alkynyl [wherein said C₁₋₄alkyl, C₂₋₄alkenyl and C₂₋₄alkynyl are optionally substituted by one or more groups selected from R^d], C₁₋₄alkanoyl, C₁₋₄alkoxycarbonyl, heterocyclic group, C₁₋₄alkylS(O)_a wherein a is 0 to 2 [optionally substituted by hydroxy], *N'*-(C₁₋₄alkyl)ureido, *N',N'*-di-(C₁₋₄alkyl)ureido, *N'*-(C₁₋₄alkyl)-*N*-(C₁₋₄alkyl)ureido, *N',N'*-di-(C₁₋₄alkyl)-*N*-(C₁₋₄alkyl)ureido, *N*-C₁₋₄alkylamino, *N,N*-di-(C₁₋₄alkyl)amino, *N*-(C₁₋₄alkyl)sulphamoyl, *N,N*-di-(C₁₋₄alkyl)sulphamoyl, *N*-C₁₋₄alkylcarbamoyl, *N,N*-di-(C₁₋₄alkyl)carbamoyl and C₁₋₄alkanoylamino;

20 and also independently, or in addition to, the above substituents, **Q₁** may be optionally substituted by one to two substituents independently selected from aryl, C₃₋₈cycloalkyl and a heterocyclic group; wherein said aryl, C₃₋₈cycloalkyl or heterocyclic group may be optionally substituted on a ring carbon by one or more groups selected from R^e; and wherein if said heterocyclic group contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R^f;

30 **Q₂** is optionally substituted on a ring carbon by one to four substituents independently selected from halo, hydroxy, mercapto, nitro, formyl, formamido, carboxy, cyano, amino, ureido, carbamoyl, sulphamoyl, C₁₋₄alkyl, C₂₋₄alkenyl, C₂₋₄alkynyl, C₁₋₄alkoxy [wherein said

C₁₋₄alkyl, C₂₋₄alkenyl, C₂₋₄alkynyl and C₁₋₄alkoxy are optionally substituted by one or more groups selected from R^g], C₁₋₄alkanoyl, C₁₋₄alkoxycarbonyl, heterocyclic group, C₁₋₄alkylS(O)_a wherein a is 0 to 2 [optionally substituted by hydroxy], N'-(C₁₋₄alkyl)ureido,

N',N'-di-(C₁₋₄alkyl)ureido, N'-(C₁₋₄alkyl)-N-(C₁₋₄alkyl)ureido,

- 5 N',N'-di-(C₁₋₄alkyl)-N-(C₁₋₄alkyl)ureido, N-C₁₋₄alkylamino, N,N-di-(C₁₋₄alkyl)amino, N-(C₁₋₄alkyl)sulphamoyl, N,N-di-(C₁₋₄alkyl)sulphamoyl, N-C₁₋₄alkylcarbamoyl, N,N-di-(C₁₋₄alkyl)carbamoyl, C₂₋₄alkenyloxy, C₂₋₄alkynyloxy, C₁₋₄alkanoylamino;

and also independently, or in addition to, the above substituents, Q₂ may be optionally substituted by one to two substituents independently selected from aryl, C₃₋₈cycloalkyl or a

- 10 heterocyclic group; wherein said aryl, C₃₋₈cycloalkyl or heterocyclic group may be optionally substituted on a ring carbon by one or more groups selected from R^h; and wherein if said heterocyclic group contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from Rⁱ;

R^c, R^d and R^e are independently selected from hydroxy, halo, amino, cyano, formyl,

- 15 formamido, carboxy, nitro, mercapto, carbamoyl, sulphamoyl, N-C₁₋₄alkylamino, N,N-di-(C₁₋₄alkyl)amino, C₁₋₄alkanoyl, C₁₋₄alkanoyloxy, C₁₋₄alkoxy, C₁₋₄alkoxycarbonyl, N-C₁₋₄alkylcarbamoyl, N,N-di-(C₁₋₄alkyl)carbamoyl, C₁₋₄alkanoylamino, C₁₋₄alkylS(O)_a wherein a is 0 to 2, C₁₋₄alkylsulphonylamino, N-(C₁₋₄alkyl)sulphamoyl, N-(C₁₋₄alkyl)₂sulphamoyl, N-(C₁₋₄alkyl)carbamoyl, N-(C₁₋₄alkyl)₂carbamoyl, phenyl,

- 20 phenylthio, phenoxy, C₃₋₈cycloalkyl and a heterocyclic group; wherein said phenyl, phenylthio, phenoxy, C₃₋₈cycloalkyl or heterocyclic group may be optionally substituted on a ring carbon by one or more groups selected from R^j; and wherein if said heterocyclic group contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R^k;

- 25 R^a, R^c, R^h and R^l are independently selected from hydroxy, halo, amino, cyano, formyl, formamido, carboxy, nitro, mercapto, carbamoyl, sulphamoyl, C₁₋₄alkyl [optionally substituted by one or more groups selected from halo, cyano, amino, N-C₁₋₄alkylamino, N,N-di-(C₁₋₄alkyl)amino or hydroxy], C₂₋₄alkenyl [optionally substituted by one or more groups selected from halo], C₂₋₄alkynyl, N-C₁₋₄alkylamino, N,N-di-(C₁₋₄alkyl)amino,
- 30 C₁₋₄alkanoyl, C₁₋₄alkanoyloxy, C₁₋₄alkoxy [optionally substituted by one or more groups selected from halo], C₁₋₄alkoxycarbonyl, N-C₁₋₄alkylcarbamoyl, N,N-di-(C₁₋₄alkyl)carbamoyl, C₁₋₄alkanoylamino, C₁₋₄alkylS(O)_a wherein a is 0 to 2, C₁₋₄alkylsulphonylamino,

N-(C₁₋₄alkyl)sulphamoyl, *N*-(C₁₋₄alkyl)₂sulphamoyl, phenyl, C₃₋₈cycloalkyl and a heterocyclic group; and

R^b, R^f, Rⁱ and R^k are independently selected from C₁₋₄alkyl, C₁₋₄alkanoyl, C₁₋₄alkylsulphonyl, carbamoyl, *N*-(C₁₋₄alkyl)carbamoyl, *N,N*-(C₁₋₄alkyl)carbamoyl, benzyl, 5 benzyloxycarbonyl, benzoyl and phenylsulphonyl; or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof.

“Aryl” is a fully or partially unsaturated, mono or bicyclic carbon ring that contains 4-12 atoms. Preferably “aryl” is a monocyclic ring containing 5 or 6 atoms or a bicyclic ring containing 9 or 10 atoms. More preferably “aryl” is phenyl, naphthyl, tetralinyl or indanyl.

10 Particularly “aryl” is phenyl, naphthyl or indanyl. More particularly “aryl” is phenyl.

A “carbon linked heteroaryl” is a fully unsaturated, 5- or 6- membered monocyclic ring or 9- or 10- membered bicyclic ring of which at least one atom is chosen from nitrogen, sulphur or oxygen. This ring is linked via a carbon atom to the -NH- (for Q₁) or G (for Q₂). Preferably “carbon linked heteroaryl” is furanyl, thienyl, pyrrolyl, oxazolyl, isoxazolyl, 15 thiazolyl, isothiazolyl, imidazolyl, pyrazolyl, furazanyl, triazolyl, thiadiazolyl, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, triazinyl, indolyl, quinolyl or benzimidazolyl. More preferably “carbon linked heteroaryl” is pyridyl, thiazolyl or pyrazolyl. Particularly “carbon linked heteroaryl” is pyridyl.

A “heterocyclic group” is a saturated, partially saturated or unsaturated, mono or 20 bicyclic ring containing 4-12 atoms of which at least one atom is chosen from nitrogen, sulphur or oxygen, which may, unless otherwise specified, be carbon or nitrogen linked, wherein a -CH₂- group can optionally be replaced by a -C(O)-, and a ring sulphur atom may be optionally oxidised to form S-oxide(s). Preferably a “heterocyclic group” is pyrrolidinyl, morpholino, piperidyl, quinuclidinyl, pyridyl, pyranyl, pyrrolyl, isothiazolyl, indolyl, 25 quinolyl, thienyl, furyl, 1,3-benzodioxolyl, thiadiazolyl, piperazinyl, thiazolidinyl, pyrrolidinyl, succinimidyl, thiomorpholino, pyrazolyl, pyrrolinyl, homopiperazinyl, tetrahydropyranyl, imidazolyl, pyrimidyl, pyrazinyl, pyridazinyl, isoxazolyl, phthalimidyl, 4-pyridone, 1-isoquinolone, 2-pyrrolidone, 4-thiazolidone, imidazo[1,2-a]pyridine or 3-aza-8-oxabicyclo[3,2,1]hexane. More preferably a “heterocyclic group” is pyrrolidinyl, morpholino, 30 piperidyl, quinuclidinyl, piperazinyl, succinimidyl, imidazolyl or phthalimidyl.

In this specification the term “alkyl” includes both straight and branched chain alkyl groups but references to individual alkyl groups such as “propyl” are specific for the straight

chain version only. An analogous convention applies to other generic terms. "Halo" is fluoro, chloro, bromo and iodo.

Examples of **C₂₋₄alkenyl** are vinyl and allyl; examples of **C₂₋₆alkenyl** are C₃₋₅alkenyl, vinyl and allyl; an example of **C₃₋₆alkenyl** is allyl; an examples of **C₃₋₆alkynyl** are C₃₋₅alkynyl and propyn-2-yl; examples of **C₂₋₄alkynyl** are ethynyl and propyn-2-yl; examples of **C₂₋₆alkynyl** are ethynyl and propyn-2-yl; examples of **C₁₋₄alkanoyl** are acetyl and propionyl; examples of **C₁₋₄alkoxycarbonyl** are C₁₋₃alkoxycarbonyl, C₁₋₂alkoxycarbonyl, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl and *tert*-butoxycarbonyl; examples of **C₁₋₄alkylene** are methylene, ethylene and propylene; examples of **C₁₋₄alkyl** are C₁₋₃alkyl, C₁₋₂alkyl, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, *sec*-butyl and *tert*-butyl; examples of **C₁₋₆alkyl** are methyl, ethyl, propyl, isopropyl, butyl, isobutyl, *sec*-butyl, *tert*-butyl and 3-methylbutyl; examples of **C₁₋₄alkoxy** are C₁₋₃alkoxy, C₁₋₂alkoxy, methoxy, ethoxy, propoxy, isopropoxy and butoxy; an example of **C₂₋₄alkenyloxy** is allyloxy; an example of **C₂₋₄alkynyloxy** is propynyloxy; examples of **C₁₋₄alkylS(O)_a** wherein **a** is 0 to 2 are C₁₋₃alkylsulphanyl, methylthio, ethylthio, propylthio, methylsulphinyl, ethylsulphinyl, propylsulphinyl, mesyl, ethylsulphonyl and propylsulphonyl; examples of **N-C₁₋₄alkylcarbamoyl** are *N*-methylcarbamoyl, *N*-ethylcarbamoyl and *N*-propylcarbamoyl; examples of **N,N-di-(C₁₋₄alkyl)-carbamoyl** are *N,N*-dimethylcarbamoyl, *N*-ethyl-*N*-methylcarbamoyl and *N,N*-diethylcarbamoyl; examples of **N-C₁₋₄alkylamino** are *N*-(C₁₋₃alkyl)amino, *N*-(C₁₋₂alkyl)amino, methylamino, ethylamino and propylamino; examples of **N,N-di-(C₁₋₄alkyl)amino** are *N,N*-di-(C₁₋₃alkyl)amino, *N,N*-di-(C₁₋₂alkyl)amino, dimethylamino, *N*-ethyl-*N*-methylamino, diethylamino, *N*-methyl-*N*-propylamino and dipropylamino; examples of **C₁₋₄alkanoylamino** are acetamido, propionamido and butyramido; examples of **C₃₋₈cycloalkyl** are cyclopropyl, cyclopentyl and cyclohexyl; examples of **C₁₋₄alkanoyl** are acetyl and propionyl; examples of **C₁₋₄alkanoyloxy** are acetyloxy and propionyloxy; examples of **N'-(C₁₋₄alkyl)ureido** are *N'*-methylureido and *N'*-ethylureido; examples of **N',N'-di-(C₁₋₄alkyl)ureido** are *N',N'*-dimethylureido, *N',N'*-diisopropylureido and *N'*-methyl-*N'*-propylureido; examples of **N'-(C₁₋₄alkyl)-N-(C₁₋₄alkyl)ureido** are *N'*-methyl-*N*-ethylureido and *N'*-methyl-*N*-methylureido; examples of **N',N'-di-(C₁₋₄alkyl)-N-(C₁₋₄alkyl)ureido** are *N',N'*-dimethyl-*N*-ethylureido and *N'*-methyl-*N'*-propyl-*N*-butylureido; examples of **N-(C₁₋₄alkyl)sulphamoyl** are *N*-methylsulphamoyl and *N*-isopropylsulphamoyl; examples of

N,N-di-(C₁₋₄alkyl)sulphamoyl are *N*-methyl-*N*-ethylsulphamoyl and *N,N*-dipropylsulphamoyl; examples of C₁₋₄alkylsulphonylamino are mesylamino, ethylsulphonylamino and propylsulphonylamino; examples of heterocyclic group-O- are piperidinyloxy, pyridyloxy and pyrimidinyloxy; examples of C_{1,2}alkoxyC_{1,2}alkyl are methoxymethyl and ethoxyethyl; examples of heterocyclic group-C(O)- are piperazinylcarbonyl, pyridylcarbonyl and pyrimidinylcarbonyl.

A suitable pharmaceutically acceptable salt of a pyrimidine derivative of the invention is, for example, an acid-addition salt of a pyrimidine derivative of the invention which is sufficiently basic, for example, an acid-addition salt with, for example, an inorganic or organic acid, for example hydrochloric, hydrobromic, sulphuric, phosphoric, trifluoroacetic, citric or maleic acid. In addition a suitable pharmaceutically acceptable salt of a pyrimidine derivative of the invention which is sufficiently acidic is an alkali metal salt, for example a sodium or potassium salt, an alkaline earth metal salt, for example a calcium or magnesium salt, an ammonium salt or a salt with an organic base which affords a physiologically acceptable cation, for example a salt with methylamine, dimethylamine, trimethylamine, piperidine, morpholine or tris-(2-hydroxyethyl)amine.

The compounds of the formula (I) may be administered in the form of a pro-drug which is broken down in the human or animal body to give a compound of the formula (I). Examples of pro-drugs include *in vivo* hydrolysable esters of a compound of the formula (I).

An *in vivo* hydrolysable ester of a compound of the formula (I) containing carboxy or hydroxy group is, for example, a pharmaceutically acceptable ester which is hydrolysed in the human or animal body to produce the parent acid or alcohol. Suitable pharmaceutically acceptable esters for carboxy include C₁₋₆alkoxymethyl esters for example methoxymethyl, C₁₋₆alkanoyloxymethyl esters for example pivaloyloxymethyl, phthalidyl esters, C₃₋₈cycloalkoxycarbonyloxyC₁₋₆alkyl esters for example 1-cyclohexylcarbonyloxyethyl; 1,3-dioxolen-2-onylmethyl esters for example 5-methyl-1,3-dioxolen-2-onylmethyl; and C₁₋₆alkoxycarbonyloxyethyl esters for example 1-methoxycarbonyloxyethyl and may be formed at any carboxy group in the compounds of this invention.

An *in vivo* hydrolysable ester of a compound of the formula (I) containing a hydroxy group includes inorganic esters such as phosphate esters and α -acyloxyalkyl ethers and related compounds which as a result of the *in vivo* hydrolysis of the ester breakdown to give the parent hydroxy group. Examples of α -acyloxyalkyl ethers include acetoxymethoxy and

2,2-dimethylpropionyloxy-methoxy. A selection of *in vivo* hydrolysable ester forming groups for hydroxy include alkanoyl, benzoyl, phenylacetyl and substituted benzoyl and phenylacetyl, alkoxycarbonyl (to give alkyl carbonate esters), dialkylcarbamoyl and *N*-(dialkylaminoethyl)-*N*-alkylcarbamoyl (to give carbamates), dialkylaminoacetyl and carboxyacetyl. Examples of substituents on benzoyl include morpholino and piperazino linked from a ring nitrogen atom via a methylene group to the 3- or 4- position of the benzoyl ring.

Some compounds of the formula (I) may have chiral centres and/or geometric isomeric centres (E- and Z- isomers), and it is to be understood that the invention encompasses all such optical, diastereo-isomers and geometric isomers that possess CDK and/or FAK inhibitory activity.

The invention relates to any and all tautomeric forms of the compounds of the formula (I) that possess CDK and/or FAK inhibitory activity.

It is also to be understood that certain compounds of the formula (I) can exist in solvated as well as unsolvated forms such as, for example, hydrated forms. It is to be understood that the invention encompasses all such solvated forms which possess CDK and/or FAK inhibitory activity.

Particular preferred compounds of the invention comprise a pyrimidine derivative of the formula (I), or pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, wherein R¹, Q₁, Q₂, and G have any of the meanings defined hereinbefore, or any of the following values. Such values may be used where appropriate with any of the definitions, claims or embodiments defined hereinbefore or hereinafter.

Preferably Q₁ and Q₂ are independently selected from phenyl and pyridyl.

Preferably Q₁ is phenyl.

Preferably Q₂ is phenyl or pyridyl.

Preferably Q₁ is phenyl and Q₂ is selected from phenyl and pyridyl.

Preferably one of Q₁ and Q₂ or both of Q₁ and Q₂ is substituted on a ring carbon by one substituent selected from *N,N*-di-(C₁₋₂alkyl)amino, heterocyclic group, heterocyclic group-O-, substituted C₁₋₂alkyl, substituted C₁₋₂alkoxy, substituted C₁₋₂alkoxycarbonyl, substituted *N*-(C₁₋₂alkyl)amino, substituted C₁₋₂alkoxyC₁₋₂alkyl and substituted C₂₋₄alkynyl; wherein said substituents for C₁₋₂alkyl, C₁₋₂alkoxy, C₁₋₂alkoxycarbonyl, *N*-(C₁₋₂alkyl)amino, C₁₋₂alkoxyC₁₋₂alkyl and C₂₋₄alkynyl are selected from hydroxy, carboxy, amino, heterocyclic group, heterocyclic group-C(O)-, *N*-C₁₋₄alkylamino and *N,N*-di-(C₁₋₄alkyl)amino; wherein any

heterocyclic group is optionally substituted on a ring carbon by one or more groups selected from R^a; and wherein if any heterocyclic group contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R^b.

More preferably one of Q₁ and Q₂ or both of Q₁ and Q₂ is substituted on a ring carbon
5 by one substituent selected from *N,N*-di-(C₁₋₂alkyl)amino, piperazino (optionally substituted on the 4-nitrogen by methyl), piperidin-3-yloxy (optionally substituted on nitrogen by methyl), piperidin-4-yloxy (optionally substituted on nitrogen by methyl), substituted C₁₋₂alkyl, substituted C₁₋₂alkoxy, substituted C₁₋₂alkoxycarbonyl, substituted *N*-(C₁₋₂alkyl)amino, substituted C₁₋₂alkoxyC₁₋₂alkyl and substituted C₂₋₄alkynyl; wherein said
10 substituents for C₁₋₂alkyl, C₁₋₂alkoxy, C₁₋₂alkoxycarbonyl, *N*-(C₁₋₂alkyl)amino, C₁₋₂alkoxyC₁₋₂alkyl and C₂₋₄alkynyl are selected from hydroxy, carboxy, amino, succinimid-1-yl, piperidin-3-yl (optionally substituted on nitrogen by methyl), phthalimid-1-yl, morpholino, quinuclidin-3-yl (optionally substituted by hydroxy), piperidin-4-yl, pyrrolidin-1-yl, piperazino (optionally substituted on nitrogen by methyl), imidazol-1-yl, piperidino,
15 piperazinocarbonyl (optionally substituted on nitrogen by isopropyl), *N*-C₁₋₄alkylamino and *N,N*-di-(C₁₋₄alkyl)amino.

Particularly one of Q₁ and Q₂ or both of Q₁ and Q₂ is substituted on a ring carbon by one substituent selected from dimethylamino, 4-methylpiperazino, aminomethyl, 2-hydroxyethoxymethyl, succinimid-1-ylmethyl, 2-pyrrolidin-1-ylethyl, 2-aminoethyl, piperid-
20 4-yloxy, 1-methylpiperid-4-yloxy, 1-methylpiperid-3-yloxy, carboxymethoxy, 1-methylpiperid-2-ylmethoxy, 1-methylpiperid-3-ylmethoxy, piperid-4-ylmethoxy, 4-isopropylpiperazinocarbonylmethoxy, 2-phthalimid-1-ylethoxy, 2-morpholinoethoxy, 2-dimethylaminoethoxy, 2-diethylaminoethoxy, 2-(4-methylpiperazino)ethoxy, 2-imidazol-1-ylethoxy, 2-pyrrolidin-1-ylethoxy, 2-aminoethynyl, 2-dimethylaminoethynyl, 2-
25 methylaminoethynyl, 2-(3-hydroxyquinuclidin-3-yl)ethynyl, 2-morpholinoethoxymethyl, 2-diethylaminoethoxymethyl, 2-pyrrolidin-1-ylethoxymethyl, 2-(4-methylpiperazino)ethoxymethyl, 2-diethylaminoethoxycarbonyl, 2-piperidinoethylamino or 2-isopropylaminoethylamino.

More particularly one of Q₁ and Q₂ or both of Q₁ and Q₂ is substituted on a ring carbon
30 by one substituent selected from 1-methylpiperid-4-yloxy, carboxymethoxy, 2-dimethylaminoethoxy, 2-methylaminoethynyl, 2-piperidinoethylamino or 2-isopropylaminoethylamino.

Preferably it is Q_1 that is substituted on a ring carbon by one substituent selected from N -(C_{1-2} alkyl)amino, N,N -di-(C_{1-2} alkyl)amino, phenyl, heterocyclic group, phenoxy, heterocyclic group-O-, substituted C_{1-2} alkyl, substituted C_{1-2} alkoxy, substituted C_{1-2} alkoxycarbonyl, substituted N -(C_{1-2} alkyl)amino, substituted C_{1-2} alkoxy C_{1-2} alkyl, substituted C_{2-4} alkenyl and substituted C_{2-4} alkynyl; wherein said substituents for C_{1-2} alkyl, C_{1-2} alkoxy, C_{1-2} alkoxycarbonyl, N -(C_{1-2} alkyl)amino, C_{1-2} alkoxy C_{1-2} alkyl, C_{2-4} alkenyl and C_{2-4} alkynyl are selected from halo, hydroxy, mercapto, nitro, formyl, formamido, carboxy, cyano, amino, ureido, carbamoyl, sulphamoyl, C_{1-4} alkanoyl, C_{1-4} alkoxycarbonyl, phenyl, heterocyclic group, benzoyl, heterocyclic group-C(O)-, C_{1-4} alkylS(O)_a wherein a is 0 to 2, N' -(C_{1-4} alkyl)ureido, N',N' -di-(C_{1-4} alkyl)ureido, N' -(C_{1-4} alkyl)- N -(C_{1-4} alkyl)ureido, N',N' -di-(C_{1-4} alkyl)- N -(C_{1-4} alkyl)ureido, N - C_{1-4} alkylamino, N,N -di-(C_{1-4} alkyl)amino, N -(C_{1-4} alkyl)sulphamoyl, N,N -di-(C_{1-4} alkyl)sulphamoyl, N - C_{1-4} alkylcarbamoyl, N,N -di-(C_{1-4} alkyl)carbamoyl and C_{1-4} alkanoylamino; wherein any phenyl, benzyl, benzoyl or heterocyclic group is optionally substituted on a ring carbon by one or more groups selected from R^a ; and wherein if any heterocyclic group contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R^b , and more preferably Q_1 is unsubstituted apart from the one substituent selected from this list.

More preferably Q_1 is substituted in the para- or meta- position relative to the -NH-.

Particularly Q_1 is substituted in the para- position relative to the -NH-.

In one aspect of the invention preferably G is -O-.

In a further aspect of the invention preferably G is -NR²-.

In one aspect of the invention when G is -NR²-, preferably R² is hydrogen.

In another aspect of the invention when G is -NR²-, preferably R² is not hydrogen.

Preferably R¹ is hydrogen, chloro or bromo.

More preferably R¹ bromo.

Preferably Q_2 is unsubstituted or substituted by one group selected from fluoro, bromo, methyl, methoxy and cyano.

More preferably Q_2 is unsubstituted or substituted by one methyl group.

Preferably Q_2 is phenyl, 2-cyanophenyl, 3-methylphenyl, 4-fluorophenyl,

4-bromophenyl, 4-methoxyphenyl or 6-methylpyrid-2-yl.

More preferably Q_2 is phenyl or 6-methylpyrid-2-yl.

Therefore, in a preferred aspect of the invention there is provided a pyrimidine

derivative of the formula (I) as depicted above, wherein:

- Q₁ and Q₂ are independently selected from phenyl and pyridyl; and Q₁ is substituted on a ring carbon by one substituent selected from *N,N*-di-(C₁₋₂alkyl)amino, heterocyclic group, heterocyclic group-O-, substituted C₁₋₂alkyl, substituted C₁₋₂alkoxy, substituted C₁₋₂alkoxycarbonyl, substituted *N*-(C₁₋₂alkyl)amino, substituted C₁₋₂alkoxyC₁₋₂alkyl and substituted C₂₋₄alkynyl; wherein said substituents for C₁₋₂alkyl, C₁₋₂alkoxy, C₁₋₂alkoxycarbonyl, *N*-(C₁₋₂alkyl)amino, C₁₋₂alkoxyC₁₋₂alkyl and C₂₋₄alkynyl are selected from hydroxy, carboxy, amino, heterocyclic group, heterocyclic group-C(O)-, *N*-C₁₋₄alkylamino and *N,N*-di-(C₁₋₄alkyl)amino; wherein any heterocyclic group is optionally substituted on a ring carbon by one or more groups selected from R^a; and wherein if any heterocyclic group contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R^b; and Q₂ is unsubstituted or substituted by one group selected from fluoro, bromo, methyl, methoxy and cyano;

G is -NH-; and

- R¹ is hydrogen, chloro or bromo;
or pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof.

Therefore, in a more preferred aspect of the invention there is provided a pyrimidine derivative of the formula (II) as depicted above, wherein:

- Q₁ is phenyl and Q₂ is selected from phenyl and pyridyl; Q₁ is substituted in the para- or meta- position relative to the -NH- by one substituent selected from dimethylamino, 4-methylpiperazino, aminomethyl, 2-hydroxyethoxymethyl, succinimid-1-ylmethyl, 2-pyrrolidin-1-ylethyl, 2-aminoethyl, piperid-4-yloxy, 1-methylpiperid-4-yloxy, 1-methylpiperid-3-yloxy, carboxymethoxy, 1-methylpiperid-2-ylmethoxy, 1-methylpiperid-3-ylmethoxy, piperid-4-ylmethoxy, 4-isopropylpiperazinocarbonylmethoxy, 2-phthalimid-1-ylethoxy, 2-morpholinoethoxy, 2-dimethylaminoethoxy, 2-diethylaminoethoxy, 2-(4-methylpiperazino)ethoxy, 2-imidazol-1-ylethoxy, 2-pyrrolidin-1-ylethoxy, 2-aminoethynyl, 2-dimethylaminoethynyl, 2-methylaminoethynyl, 2-(3-hydroxyquinuclidin-3-yl)ethynyl, 2-morpholinoethoxymethyl, 2-diethylaminoethoxymethyl, 2-pyrrolidin-1-ylethoxymethyl, 2-(4-methylpiperazino)ethoxymethyl, 2-diethylaminoethoxycarbonyl, 2-piperidinoethylamino or 2-isopropylaminoethylamino; and Q₂ is unsubstituted or substituted by one group selected from fluoro, bromo, methyl, methoxy and cyano

G is -NH-; and

R¹ is hydrogen, chloro or bromo;
or pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof.

In one aspect of the invention preferred compounds of the invention are those of Examples 2, 12, 21, 28, 30 or 38 or pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof.


In a further aspect of the invention preferred compounds of the invention include any one of the Examples or pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof.

Preferred aspects of the invention are those which relate to the compound or a pharmaceutically acceptable salt thereof.

10 A pyrimidine derivative of the formula (I), or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof, may be prepared by any process known to be applicable to the preparation of chemically-related compounds. Such processes, when used to prepare a pyrimidine derivative of the formula (I), or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof, are provided as a further feature of the invention and are illustrated
15 by the following representative examples in which, unless otherwise stated R¹, Q₁, Q₂ and G have any of the meanings defined hereinbefore for a pyrimidine derivative of the formula (I) and unless another substituent is drawn on ring Q₁ or Q₂ the ring may bear any of the substituents described hereinbefore (optionally protected as necessary). Where a substituent is drawn on ring Q₁, this includes (unless stated otherwise) the possibilities of the substituent
20 being on ring Q₂ in addition to, or instead of the substituent being on ring Q₁. Necessary starting materials may be obtained by standard procedures of organic chemistry (see for example, Advanced Organic Chemistry (Wiley-Interscience), Jerry March - also useful for general guidance on reaction conditions and reagents). The preparation of such starting materials is described within the accompanying non-limiting processes and Examples.
25 Alternatively necessary starting materials are obtainable by analogous procedures to those illustrated which are within the ordinary skill of an organic chemist.


Thus, as a further feature of the invention there are provided the following processes which comprises of:-

a) for compounds of formula (I) where G is -NR²-; reacting a pyrimidine of formula (II):



(II)

wherein L is a displaceable group as defined below, with a compound of formula (III):




(III)

5


where G is -NR²-;

b) reaction of a pyrimidine of formula (IV):



(IV)

10 wherein L is a displaceable group as defined below, with a compound of formula (V):



(V)

and thereafter if necessary:

i) converting a compound of the formula (I) into another compound of the formula (I);

15 ii) removing any protecting groups;

iii) forming a pharmaceutically acceptable salt or *in vivo* hydrolysable ester.


L is a displaceable group, suitable values for L are for example, a halo, sulphonyloxy or sulphur group, for example a chloro, bromo, methanesulphonyloxy, toluene-4-sulphonyloxy, mesyl, methylthio and methylsulphinyl.

20 Specific reaction conditions for the above reactions are as follows:-

Process a)

Pyrimidines of formula (II) and compounds of formula (III) may be reacted together:

- i) optionally in the presence of a suitable acid, for example an inorganic acid such as hydrochloric acid or sulphuric acid, or an organic acid such as acetic acid or formic acid. The reaction is preferably carried out in a suitable inert solvent or diluent, for example dichloromethane (DCM), acetonitrile, butanol, tetramethylene sulphone, tetrahydrofuran,
- 5 1,2-dimethoxyethane, *N,N*-dimethylformamide, *N,N*-dimethylacetamide or *N*-methylpyrrolidin-2-one, and at a temperature in the range, for example, 0° to 150°C, conveniently at or near reflux temperature; or
- ii) under standard Buchwald conditions (for example see *J. Am. Chem. Soc.*, **118**, 7215; *J. Am. Chem. Soc.*, **119**, 8451; *J. Org. Chem.*, **62**, 1568 and 6066) for example in the presence of
- 10 palladium acetate, in a suitable solvent for example an aromatic solvent such as toluene, benzene or xylene, with a suitable base for example an inorganic base such as caesium carbonate or an organic base such as potassium-*t*-butoxide, in the presence of a suitable ligand such as 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl and at a temperature in the range of 25 to 80°C.
- 15 Pyrimidines of the formula (II) may be prepared according to the following scheme:




wherein R^a is an optionally substituted alkyl or aryl group and L is a displaceable group as defined above. Preferably R^a is methyl, ethyl or *p*-tolyl.

Compounds of formula (III) are commercially available or are prepared by processes known in the art.

Process b)

- Pyrimidines of formula (IV) and anilines of formula (V) may be reacted together, i) in the presence of a suitable solvent for example a ketone such as acetone or an alcohol such as ethanol or butanol or an aromatic hydrocarbon such as toluene or *N*-methyl pyrrolidine, optionally in the presence of a suitable acid such as those defined above (or a suitable Lewis acid) and at a temperature in the range of 0°C to reflux, preferably reflux; or
- ii) under standard Buchwald conditions as described above.

Pyrimidines of formula (IV) are prepared according to the following scheme:




wherein L is a displaceable group as defined above.

- 10 The anilines of formula (V) are commercially available or are prepared by processes known in the art.

Pyrimidines of the formula (IVA) are commercially available or may be prepared by, for example, reacting a compound of formula (IVA) in which L is -OH (i.e. a uracil), with POCl₃ to give a compound of formula (IVA) in which L is -Cl.


- 15 Examples of conversions of a compound of formula (I) into another compound of formula (I) are:

i) where G is -NR²-; conversion of R² as hydrogen into other R² for example:



wherein L is a displaceable group;

- 20 ii) where G is -NR²-; conversion of R² as a substituted side chain into another substituted side chain, for example:



wherein Ms is methanesulphonyl, and Nu is a nucleophile that introduces a substituent that is an optional substituent for R^2 as defined in formula (I) (NB the hydroxyl moiety does not necessarily have to be on the terminal carbon as depicted above);

- 5 iii) conversion of one value of R^1 into another value of R^1 , using standard techniques, for example, conversion of R^1 as hydroxy into C_{1-4} alkoxy.

A preferred process of the invention is Process b).

It will be appreciated that certain of the various ring substituents in the compounds of the present invention may be introduced by standard aromatic substitution reactions or
 10 generated by conventional functional group modifications either prior to or immediately following the processes mentioned above, and as such are included in the process aspect of the invention. Such reactions and modifications include, for example, introduction of a substituent by means of an aromatic substitution reaction, reduction of substituents, alkylation of substituents and oxidation of substituents. The reagents and reaction conditions for such
 15 procedures are well known in the chemical art. Particular examples of aromatic substitution reactions include the introduction of a nitro group using concentrated nitric acid, the introduction of an acyl group using, for example, an acyl halide and Lewis acid (such as aluminium trichloride) under Friedel Crafts conditions; the introduction of an alkyl group using an alkyl halide and Lewis acid (such as aluminium trichloride) under Friedel Crafts
 20 conditions; and the introduction of a halo group. Particular examples of modifications include the reduction of a nitro group to an amino group by for example, catalytic hydrogenation with

a nickel catalyst or treatment with iron in the presence of hydrochloric acid with heating; oxidation of alkylthio to alkylsulphinyl or alkylsulphonyl.

It will also be appreciated that in some of the reactions mentioned herein it may be necessary/desirable to protect any sensitive groups in the compounds. The instances where protection is necessary or desirable and suitable methods for protection are known to those skilled in the art. Conventional protecting groups may be used in accordance with standard practice (for illustration see T.W. Green, *Protective Groups in Organic Synthesis*, John Wiley and Sons, 1991). Thus, if reactants include groups such as amino, carboxy or hydroxy it may be desirable to protect the group in some of the reactions mentioned herein.

10 A suitable protecting group for an amino or alkylamino group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an alkoxycarbonyl group, for example a methoxycarbonyl, ethoxycarbonyl or *t*-butoxycarbonyl group, an arylmethoxycarbonyl group, for example benzyloxycarbonyl, or an aroyl group, for example benzoyl. The deprotection conditions for the above protecting groups necessarily vary with the choice of protecting
15 group. Thus, for example, an acyl group such as an alkanoyl or alkoxycarbonyl group or an aroyl group may be removed for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide. Alternatively an acyl group such as a *t*-butoxycarbonyl group may be removed, for example, by treatment with a suitable acid as hydrochloric, sulphuric or phosphoric acid or trifluoroacetic acid and an
20 arylmethoxycarbonyl group such as a benzyloxycarbonyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon, or by treatment with a Lewis acid for example boron tris(trifluoroacetate). A suitable alternative protecting group for a primary amino group is, for example, a phthaloyl group which may be removed by treatment with an alkylamine, for example dimethylaminopropylamine, or with hydrazine.

25 A suitable protecting group for a hydroxy group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an aroyl group, for example benzoyl, or an arylmethyl group, for example benzyl. The deprotection conditions for the above protecting groups will necessarily vary with the choice of protecting group. Thus, for example, an acyl group such as an alkanoyl or an aroyl group may be removed, for example, by hydrolysis with
30 a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide. Alternatively an arylmethyl group such as a benzyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon.

A suitable protecting group for a carboxy group is, for example, an esterifying group, for example a methyl or an ethyl group which may be removed, for example, by hydrolysis with a base such as sodium hydroxide, or for example a *t*-butyl group which may be removed, for example, by treatment with an acid, for example an organic acid such as trifluoroacetic acid, or for example a benzyl group which may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon.

The protecting groups may be removed at any convenient stage in the synthesis using conventional techniques well known in the chemical art.

Many of the intermediates defined herein are novel, for example, those of the formula II and IV and these are provided as a further feature of the invention.

ASSAYS

As stated hereinbefore the pyrimidine derivative defined in the present invention possesses anti-cell-proliferation activity such as anti-cancer activity which is believed to arise from the CDK and/or FAK inhibitory activity of the compound. These properties may be assessed, for example, using the procedure set out below:-

CDK4 Inhibition Assay

The following abbreviations have been used :-

HEPES is *N*-(2-Hydroxyethyl)piperazine-*N'*-(2-ethanesulfonic acid)

DTT is Dithiothreitol

PMSF is Phenylmethylsulfonyl fluoride

The compounds were tested in an *in vitro* kinase assay in 96 well format using Scintillation Proximity Assay (SPA - obtained from Amersham) for measuring incorporation of [γ -33-P]-Adenosine Triphosphate into a test substrate (GST-Retinoblastoma). In each well was placed the compound to be tested (diluted in DMSO and water to correct concentrations) and in control wells either p16 as an inhibitor control or DMSO as a positive control.

Approximately 0.5 μ l of CDK4/Cyclin D1 partially-purified enzyme (amount dependent on enzyme activity) diluted in 25 μ l incubation buffer was added to each well then 20 μ l of GST-Rb/ATP/ATP33 mixture (containing 0.5 μ g GST-Rb and 0.2 μ M ATP and 0.14 μ Ci [γ -33-P]-Adenosine Triphosphate), and the resulting mixture shaken gently, then incubated at room temperature for 60 minutes.

To each well was then added 150 μ L stop solution containing (0.8mg/well of Protein A-PVT SPA bead (Amersham)), 20pM/well of Anti-Glutathione Transferase, Rabbit IgG

(obtained from Molecular Probes), 61mM EDTA and 50mM HEPES pH 7.5 containing 0.05% sodium azide.

The plates were sealed with Topseal-S plate sealers, left for two hours then spun at 2500rpm, 1124xg., for 5 minutes. The plates were read on a Topcount for 30 seconds per well.

5 The incubation buffer used to dilute the enzyme and substrate mixes contained 50mM HEPES pH7.5, 10mM MnCl₂, 1mM DTT, 100μM Sodium vanadate, 100μM NaF, 10mM Sodium Glycerophosphate, BSA (1mg/ml final).

As a control, another known inhibitor of CDK4 may be used in place of p16.

Test substrate

10 In this assay only part of the retinoblastoma (Science 1987 Mar13;235(4794):1394-1399; Lee W.H., Bookstein R., Hong F., Young L.J., Shew J.Y., Lee E.Y.) was used, fused to a GST tag. PCR of retinoblastoma amino acids 379-928 (obtained from retinoblastoma plasmid ATCC pLRbRNL) was performed, and the sequence cloned into pGEX 2T fusion vector (Smith D.B. and Johnson, K.S. Gene 67, 31 (1988); which contained
15 a tac promoter for inducible expression, internal lac I^q gene for use in any E.Coli host, and a coding region for thrombin cleavage - obtained from Pharmacia Biotech) which was used to amplify amino acids 792-928. This sequence was again cloned into pGEX 2T.

The retinoblastoma 792-928 sequence so obtained was expressed in E.Coli (BL21 (DE3) pLysS cells) using standard inducible expression techniques, and purified as follows.

20 E.coli paste was resuspended in 10ml/g of NETN buffer (50mM Tris pH 7.5, 120mM NaCl, 1mM EDTA, 0.5%v/v NP-40, 1mM PMSF, 1ug/ml leupeptin, 1ug/ml aprotinin and 1ug/ml pepstatin) and sonicated for 2 x 45 seconds per 100ml homogenate. After centrifugation, the supernatant was loaded onto a 10ml glutathione Sepharose column (Pharmacia Biotech, Herts, UK), and washed with NETN buffer. After washing with kinase
25 buffer (50mM HEPES pH 7.5, 10mM MgCl₂, 1mM DTT, 1mM PMSF, 1ug/ml leupeptin, 1ug/ml aprotinin and 1ug/ml pepstatin) the protein was eluted with 50mM reduced glutathione in kinase buffer. Fractions containing GST-Rb(792-927) were pooled and dialysed overnight against kinase buffer. The final product was analysed by Sodium Dodeca Sulfate (SDS) PAGE (Polyacrylamide gel) using 8-16% Tris-Glycine gels (Novex, San Diego, USA).

30 CDK4 and Cyclin D1

CDK4 and Cyclin D1 were cloned from RNA from MCF-7 cell line (obtained from ATCC number:HTB22, breast adenocarcinoma line) as follows. The RNA was prepared from

MCF-7 cells, then reverse transcribed using oligo dT primers. PCR was used to amplify the complete coding sequence of each gene [CDK4 amino acids 1-303; Ref. Cell 1992 Oct 16; 71(2): 323-334; Matsushime H., Ewen M.E., Stron D.K., Kato J.Y., Hanks S.K., Roussel M.F., Sherr C.J. and Cyclin D1 amino acids 1-296; Ref. Cold Spring Harb. Symp. Quant. Biol., 1991; 56:93-97; Arnold A., Motokura T., Bloom T., Kronenberg, Ruderman J., Juppner H., Kim H.G.].

After sequencing the PCR products were cloned using standard techniques into the insect expression vector pVL1393 (obtained from Invitrogen 1995 catalogue number : V1392-20). The PCR products were then dually expressed [using a standard virus Baculogold co-infection technique] into the insect SF21 cell system (Spodoptera Frugiperda cells derived from ovarian tissue of the Fall Army Worm -Commercially available).

The following Example provides details of the production of Cyclin D1/CDK4 in SF21 cells (in TC100 + 10% FBS(TCS) + 0.2% Pluronic) having dual infection MOI 3 for each virus of Cyclin D1 & CDK4.

15 Example production of Cyclin D1/CDK4

SF21 cells grown in a roller bottle culture to 2.33×10^6 cells/ml were used to inoculate 10 x 500 ml roller bottles at 0.2×10^6 cells/ml. The roller bottles were incubated on a roller rig at 28°C.

After 3 days (72 hrs.) the cells were counted, and the average from 2 bottles found to be 1.86×10^6 cells/ml. (99% viable). The cultures were then infected with the dual viruses at an MOI 3 for each virus.

10 x 500ml were infected with JS303 Cyclin D1 virus titre - 9×10^7 pfu/ml. JS304 CDK4 virus titre - 1×10^8 pfu/ml.

Cyclin D1 $\frac{1.86 \times 10^6 \times 500 \times 3}{0.9 \times 10^8} = 31$ ml of virus for each 500 ml. bottle.

25 0.9×10^8

CDK4 $\frac{1.86 \times 10^6 \times 500 \times 3}{1 \times 10^8} = 28$ ml of virus for each 500 ml. bottle.

1×10^8

The viruses were mixed together before addition to the cultures, and the cultures returned to the roller rig 28°C.

30 After 3 days (72 hrs.) post infection the 5 Litres of culture was harvested. The total cell count at harvest was 1.58×10^6 cells/ml.(99% viable). The cells were spun out at 2500rpm, 30 mins., 4°C in Heraeus Omnifuge 2.0 RS in 250 ml lots. The supernatant was

discarded. 20 pellets of $\sim 4 \times 10^8$ cells/pellet were snap frozen in LN_2 and stored at -80°C in CCRF cold room. The SF21 cells were then hypotonically lysed by resuspending in lysis buffer (50mM HEPES pH 7.5, 10mM magnesium chloride, 1mM DTT, 10mM

glycerophosphate, 0.1mM PMSF, 0.1mM sodium fluoride, 0.1mM sodium orthovanadate,

5 5ug/ml aprotinin, 5ug/ml leupeptin and 20% w/v sucrose), and adding ice cold deionised water. After centrifugation, the supernatant was loaded onto a Poros HQ/M 1.4/100 anion exchange column (PE Biosystems, Hertford, UK). CDK4 and Cyclin D1 were coeluted with 375mM NaCl in lysis buffer, and their presence checked by western blot, using suitable anti-CDK4 and anti-Cyclin D1 antibodies (obtained from Santa Cruz Biotechnology,

10 California, US).

p16 control (Nature 366.:704-707; 1993; Serrano M, Hannon GJ, Beach D)

p16 (the natural inhibitor of CDK4/Cyclin D1) was amplified from HeLa cDNA (Hela cells obtained from ATCC CCL2, human epitheloid carcinoma from cervix; Cancer Res. 12: 264, 1952), cloned into pTB 375 NBSE which had a 5' His tag, and transformed using

15 standard techniques into BL21 (DE3) pLysS cells (obtained from Promega; Ref. Studier F.W. and Moffat B.A., J. Mol. Biol., 189, 113, 1986). A 1 litre culture was grown to the appropriate OD then induced with IPTG to express p16 overnight. The cells were then lysed by sonication in 50mM sodium phosphate, 0.5M sodium chloride, PMSF, 0.5 $\mu\text{g}/\text{ml}$ leupeptin and 0.5 $\mu\text{g}/\text{ml}$ aprotinin. The mixture was spun down, the supernatant added to nickel chelate beads and
20 mixed for 1 $\frac{1}{2}$ hours. The beads were washed in sodium phosphate, NaCl pH 6.0 and p16 product eluted in sodium phosphate, NaCl pH 7.4 with 200mM imidazole.

The pTB NBSE was constructed from pTB 375 NBPE as follows :-

pTB375

The background vector used for generation of pTB 375 was pZEN0042 (see UK patent
25 2253852) and contained the tetA/tetR inducible tetracycline resistance sequence from plasmid RP4 and the cer stability sequence from plasmid pKS492 in a pAT153 derived background.

pTB375 was generated by the addition of an expression cassette consisting of the T7 gene 10 promoter, multiple cloning site and T7 gene 10 termination sequence. In addition, a terminator sequence designed to reduce transcriptional readthrough from the background vector was

30 included upstream of the expression cassette.

pTB 375 NBPE

The unique EcoRI restriction site present in pTB 375 was removed. A new multiple cloning site containing the recognition sequences for the restriction enzymes NdeI, BamHI, PstI and EcoRI was introduced into pTB 375 between the NdeI and BamHI sites destroying
5 the original BamHI site present in pTB 375.

pTB 375 NBSE

A new multiple cloning site containing the recognition sequences for the restriction enzymes NdeI, BamHI, SmaI and EcoRI was introduced into pTB 375 NBPE between the NdeI and EcoRI sites. The oligonucleotide containing these restriction sites also contained 6
10 histidine codons located between the NdeI and BamHI sites in the same reading frame as the initiator codon (ATG) present within the NdeI site.

By analogy to the above, assays designed to assess inhibition of CDK2 and CDK6 may be constructed. CDK2 (EMBL Accession No. X62071) may be used together with Cyclin A or Cyclin E (see EMBL Accession No. M73812), and further details for such assays
15 are contained in PCT International Publication No. WO99/21845, the relevant Biochemical & Biological Evaluation sections of which are hereby incorporated by reference.

If using CDK2 with Cyclin E partial co-purification may be achieved as follows:- Sf21 cells are resuspended in lysis buffer (50mM Tris pH 8.2, 10mM MgCl₂, 1mM DTT, 10mM glycerophosphate, 0.1mM sodium orthovanadate, 0.1mM NaF, 1mM PMSF, 1ug/ml
20 leupeptin and 1ug/ml aprotinin) and homogenised for 2 minutes in a 10ml Dounce homogeniser. After centrifugation, the supernatant is loaded onto a Poros HQ/M 1.4/100 anion exchange column (PE Biosystems, Hertford, UK). CDK2 and Cyclin E are coeluted at the beginning of a 0-1M NaCl gradient (run in lysis buffer minus protease inhibitors) over 20 column volumes. Co-elution is checked by western blot using both anti-CDK2 and
25 anti-Cyclin E antibodies (Santa Cruz Biotechnology, California, US).

FAK3 Kinase Inhibition Assay

This assay determines the ability of a test compound to inhibit tyrosine kinase activity of human Focal Adhesion Kinase (FAK).

DNA encoding FAK is obtained by total gene synthesis (Edwards M, International
30 Biotechnology Lab 5(3), 19-25, 1987) or by cloning. These are then expressed in a suitable expression system to obtain polypeptide with tyrosine kinase activity. For example, FAK,

obtained by expression of recombinant protein in insect cells, was found to display intrinsic tyrosine kinase activity.

FAK (full length human cDNA described by Andre et al (Biochemical and Biophysical Research Communications, 1993, 190 (1): 140-147; EMBL/GenBank Accession Number L05186)) was modified such that the resulting protein when translated had a 6-histidine tag at the N-terminus immediately preceding the start methionine. Active FAK protein has been previously expressed in a baculovirus system using a similar N-terminal 6-histidine tag (Protein Expression And Purification, 1996, 7: 12-18). The human FAK cDNA was cloned into the baculovirus transplacement vector, pFastbac 1 (Life Technologies), and the recombinant construct was co-transfected into insect cells (for example *Spodoptera frugiperda* 21(Sf21)) with viral DNA to prepare recombinant baculovirus (details of the methods for the assembly of recombinant DNA molecules and the preparation and use of recombinant baculovirus can be found in standard texts for example Sambrook et al, 1989, Molecular cloning - A Laboratory Manual, 2nd edition, Cold Spring Harbour Laboratory Press and O'Reilly et al, 1992, Baculovirus Expression Vectors - A Laboratory Manual, W. H. Freeman and Co, New York. Details specific to the use of the pFastbac ('Bac to Bac') system are provided in Anderson et al., 1995, FOCUS (Life Technologies Bulletin Magazine), 17, p53.)

For expression of biologically active human FAK protein, Sf21 cells were infected with plaque-pure FAK recombinant virus at a multiplicity of infection of 3 and harvested 48 hours later. Harvested cells were washed with ice cold phosphate buffered saline solution (PBS) (10mM sodium phosphate pH7.4, 138mM sodium chloride, 2.7mM potassium chloride) then resuspended in ice cold lysis buffer (50mM HEPES pH7.5, 1mM Dithiothreitol, 100uM Sodium Fluoride, 100uM Sodium Orthovanadate, 10mM Glycerophosphate, 100uM Phenylmethylsulphonylfluoride (PMSF), 5ug/ml Aprotinin, 5ug/ml Leupeptin, 1% Tween; the PMSF being added just before use from a freshly-prepared 100mM solution in methanol) using 250µl lysis buffer per 10 million cells. The suspension was then incubated on ice for 15 minutes and centrifuged for 10 minutes at 13,000 rpm at 4°C. The supernatant (enzyme stock) was removed and aliquots made which were snap frozen in liquid nitrogen and then stored at -70°C. For a typical batch, stock enzyme was diluted 1 in 250 with enzyme diluent ((100mM HEPES pH 7.4, 0.2mM Dithiothreitol, 200uM Sodium Orthovanadate, 0.1% Triton X-100) and 50ml of freshly diluted enzyme was used for each assay well (see FAK3 protocol, below).

FAK3: *In vitro* Enzyme assay Protocol

A stock of substrate solution was prepared from a random copolymer containing tyrosine, for example Poly (Glu, Ala, Tyr) 6:3:1 (Sigma P3899), stored as 1 mg/ml stock in PBS at -20°C and diluted 1 in 500 with PBS for plate coating.

- 5 On the day before the assay 100µl of diluted substrate solution was dispensed into all wells of assay plates (Maxisorp 96 well immunoplates Life technologies, Cat. No. 439454A) which were sealed with plate sealers and left overnight at 4°C.

- On the day of the assay the substrate solution was discarded and the assay plate wells were washed once with 200µl PBST (PBS containing 0.05% v/v Tween 20) and once with
10 200µl 50mM Hepes pH7.4.

Test compounds were made up as 10mM or 30mM stocks in DMSO and then further diluted in glass distilled water diluted to a concentration 10 fold higher than the final assay concentration. 10µl of diluted compound was transferred to wells in the washed assay plates. "No compound" control wells contained 10µl glass distilled water instead of compound.

- 15 Forty microlitres of 25mM manganese chloride containing 6.25µM adenosine-5'-triphosphate (ATP) was added to all test wells. To start the reactions 50µl of freshly diluted enzyme was added to each well and the plates were incubated at 23C for 90 minutes. Then the reaction was stopped by adding 100µl of PBS containing 20mM EDTA. The liquid was then discarded and the wells were washed twice with PBST.

- 20 One hundred microlitres of mouse HRP-linked anti-phosphotyrosine antibody (Santa Cruz, Product SC 7020-HRP), diluted 1 in 1500 with PBST containing 0.5% w/v bovine serum albumin (BSA), was added to each well and the plates were incubated for 1 hour at room temperature before discarding the liquid and washing the wells twice with 200µl PBST. One hundred microlitres of 2,2'-azino-bis(3-ethylbenzthiazoline-6-sulphonic acid) (ABTS) solution,
25 freshly prepared using one 50mg ABTS tablet (Boehringer 1204 521) in 50ml freshly prepared 50mM phosphate-citrate buffer pH5.0 + 0.03% sodium perborate (made with 1 phosphate citrate buffer with sodium perborate (PCSB) capsule (Sigma P4922) per 100ml distilled water), was added to each well. Plates were then incubated for 20-60 minutes at room temperature until the absorbance value of the "no compound" control wells, measured at 405nm using a plate
30 reading spectrophotometer, was approximately 1.0.

Dose response curves were generated from the absorbance readings using Origin Software. Compounds were ranked for potency using the Inhibitory Concentration 50 (IC₅₀), as defined by Origin Software analysis.

Although the pharmacological properties of the compounds of the formula (I) vary with structural change, in general activity possessed by compounds of the formula (I) in the above assays may be demonstrated at IC₅₀ concentrations or doses in the range 250 μ M to 1nM.

When tested in the above *in vitro* assay the CDK4 inhibitory activity of Example 31 was measured as IC₅₀ = 0.679 μ M. When tested in the above *in vitro* assay the FAK inhibitory activity of Example 25 was measured as IC₅₀ = 0.218 μ M.

The *in vivo* activity of the compounds of the present invention may be assessed by standard techniques, for example by measuring inhibition of cell growth and assessing cytotoxicity. For example, further details may be found in the following references:-

- a) Attenuation of the Expression of the Focal Adhesion Kinase induces Apoptosis in Tumor Cells. Xu L-h et al. Cell Growth & Differentiation (1996) 7, p413-418;
- b) The COOH-Terminal Domain of the Focal Adhesion Kinase Induces Loss of Adhesion and Cell Death in Human Tumour Cells. Xu L-h et al. Cell Growth & Differentiation (1998) 9, p999-1005;
- c) Inhibition of pp125-FAK in Cultured Fibroblasts Results in Apoptosis. Hungerford J.E et al. The Journal of Cell Biology (1996) 135, p1383-1390;
- d) Inhibition of Focal Adhesion Kinase (FAK) Signalling in Focal Adhesions Decreases Cell Motility and Proliferation. Gilmore A.P and Romer L.H. Molecular Biology of the Cell (1996) 7, p1209-1224.

Inhibition of cell growth may be measured by staining cells with Sulforhodamine B (SRB), a fluorescent dye that stains proteins and therefore gives an estimation of amount of protein (i.e. cells) in a well (see Boyd, M. R. (1989) Status of the NCI preclinical antitumour drug discovery screen. Prin. Prac Oncol 10:1-12). Thus, the following details are provided of measuring inhibition of cell growth:-

Cells were plated in appropriate medium in a volume of 100 μ l in 96 well plates; media was Dulbecco's Modified Eagle media for MCF-7, SK-UT-1B and SK-UT-1. The cells were allowed to attach overnight, then inhibitor compounds were added at various concentrations in

a maximum concentration of 1% DMSO (v/v). A control plate was assayed to give a value for cells before dosing. Cells were incubated at 37°C, (5% CO₂) for three days.

At the end of three days TCA was added to the plates to a final concentration of 16% (v/v). Plates were then incubated at 4°C for 1 hour, the supernatant removed and the plates
5 washed in tap water. After drying, 100µl SRB dye (0.4% SRB in 1% acetic acid) was added for 30 minutes at 37°C. Excess SRB was removed and the plates washed in 1% acetic acid. The SRB bound to protein was solubilised in 10mM Tris pH7.5 and shaken for 30 minutes at room temperature. The ODs were read at 540nm, and the concentration of inhibitor causing 50% inhibition of growth was determined from a semi-log plot of inhibitor concentration
10 versus absorbance. The concentration of compound that reduced the optical density to below that obtained when the cells were plated at the start of the experiment gave the value for toxicity.

Typical IC₅₀ values for compounds of the invention when tested in the SRB assay are in the range 1mM to 1nM.

15 According to a further aspect of the invention there is provided a pharmaceutical composition which comprises a pyrimidine derivative of the formula (I), or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, as defined hereinbefore in association with a pharmaceutically acceptable diluent or carrier.

The composition may be in a form suitable for oral administration, for example as a
20 tablet or capsule, for parenteral injection (including intravenous, subcutaneous, intramuscular, intravascular or infusion) as a sterile solution, suspension or emulsion, for topical administration as an ointment or cream or for rectal administration as a suppository.

In general the above compositions may be prepared in a conventional manner using conventional excipients.

25 The pyrimidine will normally be administered to a warm-blooded animal at a unit dose within the range 5-5000 mg per square meter body area of the animal, i.e. approximately 0.1-100 mg/kg, and this normally provides a therapeutically-effective dose. A unit dose form such as a tablet or capsule will usually contain, for example 1-250 mg of active ingredient. Preferably a daily dose in the range of 1-50 mg/kg is employed. However the daily dose will
30 necessarily be varied depending upon the host treated, the particular route of administration, and the severity of the illness being treated. Accordingly the optimum dosage may be determined by the practitioner who is treating any particular patient.

According to a further aspect of the present invention there is provided a pyrimidine derivative of the formula (I), or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, as defined hereinbefore for use in a method of prophylactic or therapeutic treatment of a warm-blooded animal, such as man.

5 We have found that the pyrimidine derivatives defined in the present invention, or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, are effective cell cycle inhibitors (anti-cell proliferation agents), which property (without being bound by theory) is believed to arise from their CDK inhibitory properties. The compounds are also effective inhibitors of FAK. Accordingly the compounds of the present invention are expected to be
10 useful in the treatment of diseases or medical conditions mediated alone or in part by CDK and/or FAK enzymes, i.e. the compounds may be used to produce a CDK and/or FAK inhibitory effect in a warm-blooded animal in need of such treatment. Thus the compounds of the present invention provide a method for treating the proliferation and/or migration of malignant cells characterised by inhibition of CDK and/or FAK enzymes, i.e. the compounds
15 may be used to produce an anti-proliferative/migration effect mediated alone or in part by the inhibition of CDKs and/or FAK. The compounds may also be useful as FAK inhibitors by inducing cell-death (apoptosis). Such a pyrimidine derivative of the invention is expected to possess a wide range of anti-cancer properties as CDKs and/or FAK have been implicated in many common human cancers such as leukaemia and breast, lung, colon, rectal, stomach,
20 prostate, bladder, pancreas and ovarian cancer. Thus it is expected that a pyrimidine derivative of the invention will possess anti-cancer activity against these cancers. It is in addition expected that a pyrimidine derivative of the present invention will possess activity against a range of leukaemias, lymphoid malignancies and solid tumours such as carcinomas and sarcomas in tissues such as the liver, kidney, prostate and pancreas. In particular such
25 compounds of the invention are expected to slow advantageously the growth of primary and recurrent solid tumours of, for example, the colon, breast, prostate, lungs and skin. More particularly such compounds of the invention, or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, are expected to inhibit the growth of those primary and recurrent solid tumours which are associated with CDK and/or FAK, especially those tumours which
30 are significantly dependent on CDK and/or FAK for their growth and spread, including for example, certain tumours of the colon, breast, prostate, lung, vulva and skin.

It is further expected that a pyrimidine derivative of the present invention will possess

activity against other cell-proliferation/migration diseases in a wide range of other disease states including leukemias, fibroproliferative and differentiative disorders, psoriasis, rheumatoid arthritis, Kaposi's sarcoma, haemangioma, acute and chronic nephropathies, atheroma, atherosclerosis, arterial restenosis, autoimmune diseases, acute and chronic
5 inflammation, bone diseases and ocular diseases with retinal vessel proliferation.

Thus according to this aspect of the invention there is provided a pyrimidine derivative of the formula (I), or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, as defined hereinbefore for use as a medicament; and the use of a pyrimidine derivative of the formula (I), or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, as
10 defined hereinbefore in the manufacture of a medicament for use in the production of an anti-cancer, cell cycle inhibitory (anti-cell-proliferation) effect and/or a FAK inhibitory (anti-cell migration and/or apoptosis inducing) effect in a warm-blooded animal such as man. Particularly, a cell cycle inhibitory effect is produced at the S or G1-S phase by inhibition of CDK2, CDK4 and/or CDK6, especially CDK4 and CDK6.

15 According to a further feature of this aspect of the invention there is provided a method for producing an anti-cancer, cell cycle inhibitory (anti-cell-proliferation) effect and/or a FAK inhibitory (anti-cell migration and/or apoptosis inducing) effect in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a pyrimidine derivative as defined immediately above.
20 Particularly, an inhibitory effect is produced at the S or G1-S phase by inhibition of CDK2, CDK4 and/or CDK6, especially CDK4 and CDK6.

As stated above the size of the dose required for the therapeutic or prophylactic treatment of a particular cell-proliferation disease will necessarily be varied depending on the host treated, the route of administration and the severity of the illness being treated. A unit
25 dose in the range, for example, 1-100 mg/kg, preferably 1-50 mg/kg is envisaged.

The CDK and/or FAK inhibitory activity defined hereinbefore may be applied as a sole therapy or may involve, in addition to a compound of the invention, one or more other substances and/or treatments. Such conjoint treatment may be achieved by way of the simultaneous, sequential or separate administration of the individual components of the
30 treatment. In the field of medical oncology it is normal practice to use a combination of different forms of treatment to treat each patient with cancer. In medical oncology the other component(s) of such conjoint treatment in addition to the cell cycle inhibitory treatment

defined hereinbefore may be: surgery, radiotherapy or chemotherapy. Such chemotherapy may cover three main categories of therapeutic agent:

- (i) other cell cycle inhibitory agents that work by the same or different mechanisms from those defined hereinbefore;
- 5 (ii) cytostatic agents such as antioestrogens (for example tamoxifen, toremifene, raloxifene, droloxifene, idoxifene), progestogens (for example megestrol acetate), aromatase inhibitors (for example anastrozole, letrozole, vorazole, exemestane), antiprogesterones, antiandrogens (for example flutamide, nilutamide, bicalutamide, cyproterone acetate), LHRH agonists and antagonists (for example goserelin acetate, luprolide), inhibitors of testosterone
- 10 5 α -dihydroreductase (for example finasteride), anti-invasion agents (for example metalloproteinase inhibitors like marimastat and inhibitors of urokinase plasminogen activator receptor function) and inhibitors of growth factor function, (such growth factors include for example platelet derived growth factor and hepatocyte growth factor such inhibitors include growth factor antibodies, growth factor receptor antibodies, tyrosine kinase inhibitors and
- 15 serine/threonine kinase inhibitors); and
- (iii) antiproliferative/antineoplastic drugs and combinations thereof, as used in medical oncology, such as antimetabolites (for example antifolates like methotrexate, fluoropyrimidines like 5-fluorouracil, purine and adenosine analogues, cytosine arabinoside); antitumour antibiotics (for example anthracyclines like doxorubicin, daunomycin, epirubicin
- 20 and idarubicin, mitomycin-C, dactinomycin, mithramycin); platinum derivatives (for example cisplatin, carboplatin); alkylating agents (for example nitrogen mustard, melphalan, chlorambucil, busulphan, cyclophosphamide, ifosfamide, nitrosoureas, thiotepa); antimitotic agents (for example vinca alkaloids like vincristine and taxoids like taxol, taxotere); topoisomerase inhibitors (for example epipodophyllotoxins like etoposide and teniposide,
- 25 amsacrine, topotecan). According to this aspect of the invention there is provided a pharmaceutical product comprising a pyrimidine derivative of the formula (I) as defined hereinbefore, or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, and an additional anti-tumour substance as defined hereinbefore for the conjoint treatment of cancer. An anti-emetic may also be usefully administered, for example when using such
- 30 conjoint treatment as described above.

In addition to their use in therapeutic medicine, the compounds of formula (I) and their pharmaceutically acceptable salts are also useful as pharmacological tools in the

development and standardisation of *in vitro* and *in vivo* test systems for the evaluation of the effects of inhibitors of cell cycle activity in laboratory animals such as cats, dogs, rabbits, monkeys, rats and mice, as part of the search for new therapeutic agents.

In the above other, pharmaceutical composition, process, method, use and medicament
5 manufacture features, the alternative and preferred embodiments of the compounds of the invention described herein also apply.

The invention will now be illustrated in the following non limiting Examples, in which standard techniques known to the skilled chemist and techniques analogous to those described in these Examples may be used where appropriate, and in which, unless otherwise stated:

- 10 (i) evaporations were carried out by rotary evaporation in vacuo and work up procedures were carried out after removal of residual solids such as drying agents by filtration;
- (ii) operations were carried out at ambient temperature, typically in the range 18-25°C and in air unless stated, or unless the skilled person would otherwise operate under an atmosphere of an inert gas such as argon;
- 15 (iii) column chromatography (by the flash procedure) and medium pressure liquid chromatography (MPLC) were performed on Merck Kieselgel silica (Art. 9385) or on Merck Lichroprep RP-18 (Art. 9303) reversed-phase silica, obtained from E. Merck, Darmstadt, Germany; bond elute chromatography was performed using Varian Mega Bond Elut cartridges (10 g, order code 1225-6034), obtained from Varian Sample Preparation Products,
20 California, USA;
- (iv) yields are given for illustration only and are not necessarily the maximum attainable;
- (v) the structures of the end products of the formula (I) were generally confirmed by nuclear (generally proton) magnetic resonance (NMR) and mass spectral techniques; proton magnetic resonance chemical shift values were measured in deuterated DMSO_d₆ (unless otherwise
25 stated) on the delta scale (ppm downfield from tetramethylsilane) using a Varian Gemini 2000 spectrometer operating at a field strength of 300MHz, or a Bruker AM250 spectrometer operating at a field strength of 250MHz; and peak multiplicities are shown as follows: s, singlet; d, doublet; dd, double doublet; t, triplet; tt, triple triplet; q, quartet; tq, triple quartet; m, multiplet; br, broad; mass spectrometry (MS) was performed by electrospray on a VG
30 platform;
- (vi) unless further details are specified in the text, analytical high performance liquid chromatography (HPLC) was performed on a Waters Spherisorb ODS1 25 cm column, at a

flow rate of 2 ml/minute using acetonitrile/water/trifluoroacetic acid (60:40:0.1 v/v) as eluent, detection was at a wavelength of 254 nm, and data are quoted as retention time (RT) in minutes;

(vii) robotic synthesis was carried out using a Zymate XP robot, with solution additions via a

5 Zymate Master Laboratory Station and stirred via a Stem RS5000 Reacto-Station at 25°C;

(viii) work up and purification of reaction mixtures from robotic synthesis was carried out as follows: evaporations were carried out *in vacuo* using a Savant AES 2000; column

chromatography was performed using either an Anachem Sympur MPLC or Jones

Flashmaster MPLC systems on silica using Varian Mega Bond Elut cartridges; the structures

10 of the final products were confirmed by LCMS on a Micromass OpenLynx system using the following and are quoted as retention time (RT) in minutes:

Column: 4.6 mm x 10 cm Hichrom RPB 100Å (System A)

2.1 mm x 3 cm Waters Symmetry C18 3.5 µm (System B)

Solvent: I = Water + 0.1% formic acid,

15 II = Acetonitrile + 0.1% formic acid

Run time: 10 minutes with a 6 minute gradient from 5-95% II (System A)

5 minutes with a 4.5 minute gradient from 5-95 % II (System B)

Wavelength: 254 nm, bandwidth 10 nm

Mass detector: Platform LC

20 (ix) intermediates were not generally fully characterised and purity was assessed by thin layer chromatography (TLC), HPLC, infra-red (IR), MS or NMR analysis;

(x) where solutions are dried magnesium sulphate was the drying agent;

(xi) the following abbreviations may be used hereinbefore or hereinafter:-

DCM dichloromethane;

25 DMF *N,N*-dimethylformamide;

DMSO dimethylsulphoxide;

NMP *N*-methylpyrrolidin-2-one;

THF tetrahydrofuran.

Example 1


30 4-Anilino-5-bromo-2-[4-(4-methylpiperazino)anilino]pyrimidine

A solution of 4-(4-methylpiperazino)aniline hydrochloride (obtained as described in J. Med. Chem. 1993, 36, 2716-25; 156 mg, 0.56 mmol) in methanol (1 ml) was added to a

solution of 4-anilino-5-bromo-2-chloropyrimidine (Method 1, 250 mg, 0.90 mmol) in *n*-butanol (2 ml). The mixture was heated at 100°C for 5 hours, and the insoluble solid was collected and washed with *n*-butanol (5 ml) and diethyl ether (5 ml) to give the product as a hydrochloride salt (50 mg, 14%). NMR: 2.2 (s, 3H), 2.4 (m, 4H), 3.0 (m, 4H), 6.8 (m, 2H), 7.1 (m, 1H), 7.3-7.5 (m, 4H), 7.7 (m, 2H), 8.2 (s, 1H), 8.4 (s, 1H), 9.0 (s, 1H); MS (MH⁺): 438.9, 440.9.

Examples 2-6

The following compounds were prepared by an analogous method to that described in Example 1, starting from 4-anilino-5-bromo-2-chloropyrimidine (Method 1) and the appropriate aniline hydrochloride (obtained as described in J. Med. Chem., 1993, 36, 2716-25; Eur. Pat. Appl. EP 487252; Eur. Pat. Appl. EP 401358; J. Med. Chem., 1972, 15, 523-9; J. Med. Chem., 1985, 28, 1427):



Ex	R	NMR	MS (MH ⁺)
2 ¹	dimethylamino	2.19 (s, 6H), 2.57 (t, 2H), 3.96 (t, 2H), 6.75 (d, 2H), 7.11 (t, 1H), 7.33 (dd, 2H), 7.45 (d, 2H), 7.60 (d, 2H), 8.16 (s, 1H), 8.46 (s, 1H), 9.09 (s, 1H)	428.3, 430.3
3 ^{1,2}	phthalimido		529.9, 531.9
4 ³	morpholino	3.1-3.25 (m, 2H), 3.4-3.55 (m, 4H), 3.8-4.0 (m, 4H), 4.39 (t, 2H), 6.85 (d, 2H), 7.21 (t, 1H), 7.35-7.45 (m, 4H), 7.54 (d, 2H), 8.31 (s, 1H), 9.36 (br s, 1H), 10.03 (br s, 1H)	470, 471.9

5 ⁴	4-methyl piperazino	2.81 (s, 3H), 3.4-3.8 (m, 10H), 4.38 (t, 2H), 6.87 (d, 2H), 7.23 (t, 1H), 7.39 (d, 2H), 7.41 (dd, 2H), 7.55 (d, 2H), 8.32 (s, 1H), 9.38 (br. s, 1H), 10.05 (br s, 1H)	482.9, 484.9
6 ¹	imidazol-1-yl	4.18 (t, 2H), 4.31 (t, 2H), 6.72 (d, 2H), 6.89 (d, 1H), 7.12 (t, 1H), 7.21 (d, 1H), 7.33 (dd, 2H), 7.45 (d, 2H), 7.60 (d, 2H), 7.66 (s, 1H), 8.15 (s, 1H), 8.47 (s, 1H), 9.11 (s, 1H)	450.8, 452.8

¹ Product isolated as free base by bond elute chromatography, eluting with 0-4% 2.0M methanolic ammonia solution in DCM


² HPLC (RT): 6.33

5 ³ Reaction carried out in presence of 1.0M ethereal hydrogen chloride (2 eq) and product isolated as dihydrochloride salt

⁴ Reaction carried out in presence of 1.0M ethereal hydrogen chloride (2 eq) and product isolated as trihydrochloride salt

10 Examples 7-9


The following compounds were prepared by an analogous method to that described in Example 1, starting from the appropriate 4-anilino-2-chloro-5-halopyrimidine (Methods 2-3, or obtained as described in PCT Int. Appl. WO 9719065) and the appropriate aniline hydrochloride (obtained as described in Eur. Pat. Appl. EP 401358; J. Med. Chem., 1985, 28, 15 1427; Ger. Offen. DE 2315791), and isolating the products as free bases by bond elute chromatography eluting with 0-4% 2.0M methanolic ammonia solution in DCM:



Ex	R ¹	R ²	R ³	NMR	MS (MH ⁺)
7	Cl	2-CN	morpholino	2.44 (t, 4H), 2.62 (t, 2H), 3.57 (t, 4H), 3.98 (t, 2H), 6.63 (d, 2H), 7.29 (d, 2H), 7.44 (t, 1H), 7.63 (d, 1H), 7.75 (dt, 1H), 7.89 (d, 1H), 8.14 (s, 1H), 9.13 (s, 1H), 9.20 (s, 1H)	451, 453
8	Br	4-OMe	imidazol-1-yl	3.77 (s, 3H), 4.15 (t, 2H), 4.30 (t, 2H), 6.70 (d, 2H), 6.88 (d, 1H), 6.91 (d, 2H), 7.22 (d, 1H), 7.4-7.45 (m, 4H), 7.66 (s, 1H), 8.10 (s, 1H), 8.46 (s, 1H), 9.08 (s, 1H)	481.4, 483.4
9	H	H	pyrrolidin-1-yl	1.85-1.95 (m, 2H), 2.0-2.1 (m, 2H), 3.1-3.2 (m, 2H), 3.65-3.8 (m, 4H), 4.3 (t, 2H), 6.4 (d, 1H), 7.05 (d, 2H), 7.15-7.25 (m, 1H), 7.3-7.4 (m, 2H), 7.4-7.5 (d, 2H), 7.6-7.7 (m, 2H), 7.95 (d, 1H)	376

Examples 10-12

The following compounds were prepared by an analogous method to that described in Example 1, starting from 4-anilino-5-bromo-2-chloropyrimidine (Method 1) and the appropriate aniline hydrochloride (commercially available or obtained as described in Bioorg. Med. Chem. Lett., 1997, 7, 1921-1926; J. Med. Chem., 1984, 27, 967-78), and isolating the products as free bases by bond elute chromatography eluting with 0-4% 2.0M methanolic ammonia solution in DCM:



Ex	R	NMR	MS (MH ⁺)
10	4(2,5-dioxopyrrolidin-1-ylmethyl)	2.64 (s, 4H), 4.64 (s, 2H), 7.03 (d, 2H), 7.2 (t, 1H), 7.4 (m, 4H), 7.55 (d, 2H), 8.3 (s, 1H), 9.2 (br s, 1H), 9.82 (br s, 1H)	452, 454
11 ¹	3-dimethylamino		384.0, 386.0
12	4-carboxymethoxy	4.6 (s, 2H), 6.8 (d, 2H), 7.2 (t, 1H), 7.4 (m, 4H), 7.6 (m, 2H), 8.3 (s, 1H)	414.8, 416.8

¹ HPLC (RT): 5.73


Example 13

5 4-Anilino-5-bromo-2-[4-(aminomethyl)anilino]pyrimidine

4-Aminobenzylamine (122 mg, 1.0 mmol) and ethereal hydrogen chloride (1.0M; 1.0 ml, 1.0 mmol) were added to a solution of 4-anilino-5-bromo-2-chloropyrimidine (256 mg, 0.9 mmol) in *n*-butanol (4 ml) and the mixture was heated at 100°C for 16 hours. The insoluble solid was filtered off and dissolved in methanol (5 ml). Silica (2 g) was added and volatile material was removed by evaporation. The residue was purified by bond elute chromatography, eluting with 0-4% 2.0M methanolic ammonia solution in DCM, to give the product (163 mg, 49%): LCMS (MH⁺): 370, 372; HPLC (RT, System A): 2.04.

Examples 14-15


- 15 The following compounds were prepared using a Zymate XP robot by an analogous method to that described in Example 13, starting from 4-anilino-5-bromo-2-chloropyrimidine (Method 1) and the appropriate aniline:



Ex	R	LCMS (MH ⁺)	HPLC (RT) ¹
14	2-(diethylamino)ethoxycarbonyl	484, 486	2.26
15	2-aminoethyl	384, 386	5.78

¹ System B**Examples 16-17**

- 5 The following compounds were prepared by an analogous method to that described in Example 1, starting from 4-anilino-5-bromo-2-chloropyrimidine (Method 1) and the appropriate aniline hydrochloride (obtained as described in J. Med. Chem., 1971, 14, 836-42; PCT Int. Appl. WO 9921846), and isolating the products as free bases by bond elute chromatography eluting with 0-4% 2.0M methanolic ammonia solution in DCM:




10

Ex	R	NMR	MS (MH ⁺)
16	diethylamino	0.94 (t, 6H), 2.51 (q, 4H), 2.70 (t, 2H), 3.85 (t, 2H), 6.45 (dd, 1H), 7.01 (dd, 1H), 7.11 (t, 1H), 7.18 (d, 1H), 7.21 (s, 1H), 7.34 (dd, 2H), 7.62 (d, 2H), 8.20 (s, 1H), 8.51 (s, 1H), 9.22 (s, 1H).	456.4, 458.4
17	morpholino	2.4 (m, 4H), 2.6 (m, 2H), 3.6 (m, 4H), 3.9 (m, 2H), 6.5 (m, 1H), 7.0-7.4 (m, 6H), 7.6 (m, 2H), 8.2 (s, 1H), 8.5 (s, 1H), 9.2 (m, 1H)	470.2, 472.2

Examples 18-19

- The following compounds were prepared by an analogous method to that described in Example 1, starting from the appropriate 4-anilino-5-bromo-2-chloropyrimidine (Methods 1, 4) and 4-(4-isopropylpiperazino)carbomethoxyaniline hydrochloride (Method 13), and
- 15


isolating the products as free bases by bond elute chromatography eluting with 0-4% 2.0M methanolic ammonia solution in DCM:



Ex	R	NMR	MS (MH ⁺)
18	H	1.2 (d, 6H), 3.6-4.1 (m, 8H), 4.4 (m, 1H), 4.8 (s, 2H), 6.8 (d, 2H), 7.2 (m, 1H), 7.4 (m, 4H), 7.6 (d, 2H), 8.2 (s, 1H), 9.2 (br s, 1H), 9.4 (br s, 1H)	525.2, 526.9
19	F	1.2 (d, 6H), 2.8-3.1 (m, 2H), 3.4 (m, 2H), 3.6-4.0 (m, 2H), 4.4 (m, 2H), 4.8 (s, 2H), 6.8 (d, 2H), 7.2 (m, 2H), 7.3 (m, 2H), 7.5 (m, 2H), 8.3 (s, 1H), 9.4 (br s, 1H)	543.4, 545.3

5 Examples 20-23

The following compounds were prepared by an analogous method to that described in Example 13, starting from 4-anilino-5-bromo-2-chloropyrimidine (Method 1) and the appropriate aniline (Methods 15-17):



Ex	R	NMR	MS (MH ⁺)
20 ¹	piperidin-4-yl	1.4 (m, 2H), 1.9 (m, 2H), 2.56 (m, 2H), 2.95 (m, 2H), 4.25 (m, 1H), 6.76 (d, 2H), 7.1 (t, 1H), 7.35 (t, 2H), 7.4 (d, 2H), 7.6 (d, 2H), 8.15 (s, 1H), 8.45 (s, 1H), 9.05 (s, 1H)	440, 442
21	1-methyl piperidin-4-yl	1.5-1.7 (m, 2H), 1.8-1.95 (m, 2H), 2.15-2.3 (m, 5H), 2.6-2.8 (m, 2H), 6.75 (d, 2H), 7.1 (t, 1H), 7.3 (dd, 2H), 7.45 (d, 2H), 8.15 (s, 1H), 8.5 (s, 1H), 9.1 (s, 1H)	454.3, 456.3
22	(1-methyl piperidin-2-yl)methyl	1.2-1.6 (m, 4H), 1.6-1.8 (m, 2H), 2.0 (m, 1H), 2.1-2.2 (m, 1H), 2.2 (s, 3H), 2.7-2.8 (m, 1H), 3.8 (m, 1H), 4.0 (m, 1H), 6.75 (d, 2H), 7.1 (t, 1H), 7.3 (dd, 2H), 7.45 (d, 2H), 7.6 (d, 2H), 8.15 (s, 1H), 8.45 (s, 1H), 9.1 (s, 1H)	468.3, 470.3
23 ²	1-methyl piperidin-3-yl		454.3, 456.3

¹ Isolated directly from reaction of 4-anilino-5-bromo-2-chloropyrimidine with 4-[1-(*t*-butoxycarbonyl)piperidin-4-yl]aniline (obtained as described in PCT Int. Appl. WO 9952895)

² HPLC (RT): 3.50


5 Example 24

4-Anilino-5-bromo-2-[3-(1-methylpiperidin-3-yl)methoxyanilino]pyrimidine

A mixture of potassium carbonate (160 mg, 1.2 mmol), 4-anilino-5-bromo-2-(3-hydroxyanilino)pyrimidine (Method 10, 200 mg, 0.6 mmol) and 3-chloromethyl-1-methylpiperidine (obtained as described in Eur. J. Med. Chem. 1994, 29, 967-73; 0.11 ml, 0.62 mmol) in DMSO (2 ml) were heated at 100°C for 18 hours. Silica (1 g) was added and volatile material was removed by evaporation. The residue was loaded onto a Varian Mega Bond Elut column and the column was eluted with 0-10% 2.0M methanolic ammonia solution to give the product as a brown solid (40 mg, 15%). NMR: 1.0 (m, 1H), 1.4 (m, 1H), 1.6 (m, 3H), 1.8 (m, 2H), 2.1 (s, 3H), 2.6-2.8 (m, 2H), 3.6 (m, 2H), 6.4 (d, 1H), 7.0 - 7.4 (m, 6H), 7.6 (m, 2H), 8.2 (s, 1H), 8.5 (s, 1H), 9.2 (s, 1H); MS (MH⁺): 468.5, 470.5.

Examples 25-26

The following compounds were prepared by an analogous method to that described in Example 24, starting from 4-anilino-5-bromo-2-(4-hydroxyanilino)pyrimidine (Method 9) and the appropriate 2-(dialkylamino)ethyl chloride:




5

Ex	R	MS (MH ⁺)	HPLC (RT)
25	diethylamino	455.9, 457.9	5.72
26	pyrrolidin-1-yl	453.9, 455.9	5.52

Examples 27-30

The following compounds were prepared by an analogous method to that described in Example 1, starting from the appropriate 4-substituted 5-bromo-2-chloropyrimidine (Methods 1, 5-7) and the appropriate aniline hydrochloride (Methods 21-22), and isolating the products as free bases by bond elute chromatography eluting with 0-4% 2.0M methanolic ammonia solution in DCM:



10

Ex	X	R ¹	R ²	R ³	MS (MH ⁺)	HPLC (RT)
27	CH	Me	H	piperidino	481.0, 483.0	7.45
28	N	Me	H	piperidino	482.0, 484.0	6.65
29	CH	H	Br	<i>i</i> -PrNH	518.9, 520.9	3.03
30	CH	H	H	<i>i</i> -PrNH	441.0, 443.0	4.48

Example 31**4-Anilino-5-bromo-2-[4-(2-hydroxyethoxy)methylanilino]pyrimidine**

5 4-Anilino-5-bromo-2-chloropyrimidine (Method 1, 2.0 g, 7.03 mmol) was dissolved in *n*-butanol (40 ml) and methanol (10 ml). 4-Aminobenzyl alcohol (778 mg, 6.33 mmol) and ethereal hydrogen chloride (1.0M; 6.33 ml, 6.33 mmol) were added and the solution was heated at 100°C for 20 hours. Volatile material was removed by evaporation and the residue was dissolved in ethylene glycol (20 ml). The solution was heated at 100°C for 6 hours and

10 volatile material was removed by evaporation. The residue was purified by column chromatography, eluting with 0-4% methanol solution in DCM containing 0.5% aqueous ammonia solution, to give the product as a white solid (550 mg, 19%). NMR: 3.40 (t, 2H), 3.50 (dt, 2H), 4.37 (s, 2H), 4.57 (t, 1H), 7.09 (d, 2H), 7.10 (s, 1H), 7.15 (t, 1H), 7.36 (dd, 2H), 7.54 (d, 2H), 7.60 (d, 2H), 8.09 (s, 1H), 8.54 (s, 1H), 9.29 (s, 1H); MS (MH⁺): 415.2, 417.2.

15

Example 32**4-Anilino-5-bromo-2-{4-[2-(diethylamino)ethoxy]methylanilino}pyrimidine**


Triethylamine (33 ml, 0.241 mmol) and methanesulphonyl chloride (19 ml, 0.241 mmol) were added to a solution of 4-anilino-5-bromo-2-[4-(2-hydroxyethoxy)methylanilino]

20 pyrimidine (Example 31; 100 mg, 0.241 mmol) in DCM (5 ml) at 0°C. The solution was warmed to ambient temperature and left to stand for 1 hour. Diethylamine (2 ml) was added, and the mixture was heated at 50°C for 3 hours. The solvent was removed by evaporation, and the residue was purified by column chromatography, eluting with 0-2% methanol solution in DCM containing 0.5% aqueous ammonia solution, to give the product as a cream solid (38

25 mg, 34%). NMR (CDCl₃): 1.03 (t, 6H), 2.58 (q, 4H), 2.69 (t, 2H), 3.54 (t, 2H), 4.48 (s, 2H), 7.06 (d, 2H), 7.17 (t, 1H), 7.22 (s, 1H), 7.26 (s, 1H), 7.38 (dd, 2H), 7.49 (d, 2H), 7.58 (d, 2H), 8.15 (s, 1H); MS (MH⁺): 470.4, 472.4.

Examples 33-35

The following compounds were prepared by an analogous method to that described in Example 32, starting from 4-anilino-5-bromo-2-[4-(2-hydroxyethoxy)methylanilino]pyrimidine (Example 31) and the appropriate amine and isolating the products as di- or trihydrochloride salts:



Ex	R	NMR	MS (MH ⁺)
33 ¹	morpholino	3.0-3.2 (m, 2H), 3.3-3.45 (m, 4H), 3.75-3.85 (m, 4H), 3.9-4.0 (m, 2H), 4.42 (s, 2H), 7.17 (d, 2H), 7.23 (t, 1H), 7.40 (dd, 2H), 7.48 (d, 2H), 7.55 (d, 2H), 8.34 (s, 1H), 9.30 (s, 1H), 10.09 (s, 1H)	484.2, 486.2
34 ¹	pyrrolidin-1-yl	1.8-2.05 (m, 4H), 2.95-3.1 (m, 2H), 3.33 (t, 2H), 3.4-3.55 (m, 2H), 3.70 (t, 2H), 4.45 (s, 2H), 7.17 (d, 2H), 7.23 (t, 1H), 7.40 (dd, 2H), 7.49 (d, 2H), 7.56 (d, 2H), 8.35 (s, 1H), 9.30 (s, 1H), 10.08 (s, 1H)	467.9, 469.9
35 ²	4-methylpiperazino	2.80 (s, 3H), 3.35-3.75 (m, 10H), 3.80 (t, 2H), 4.44 (s, 2H), 7.18 (d, 2H), 7.26 (t, 1H), 7.40 (dd, 2H), 7.49 (d, 2H), 7.56 (d, 2H), 8.34 (s, 1H), 9.30 (s, 1H), 10.09 (s, 1H)	497.0, 499.0

¹ Isolated as dihydrochloride salt

² Isolated as trihydrochloride salt

Example 36**4-Anilino-5-bromo-2-[4-(2-pyrrolidin-1-ylethyl)anilino]pyrimidine**


Using an analogous method to that described in Example 32, but starting from 4-anilino-5-bromo-2-[4-(2-hydroxyethyl)anilino]pyrimidine (Method 11) and pyrrolidine, the product was obtained. MS (MH⁺): 438.1, 440.1; HPLC (RT): 5.64.


Example 37**4-Anilino-5-bromo-2-[4-(3-dimethylamino-1-propynyl)anilino]pyrimidine**

A solution of 4-anilino-5-bromo-2-(4-iodoanilino)pyrimidine (Method 12; 200 mg, 0.40 mmol), *N,N*-dimethylpropargylamine (0.09 ml, 0.85 mmol) and tetrakis (triphenylphosphine)palladium (0) (25 mg, 0.02 mmol) in pyrrolidine (3 ml) was stirred for 60 hours and then heated at 80°C for 2 hours. The mixture was diluted with DCM (10 ml) and silica (2 g) was added. Volatile material was removed by evaporation and the residue was loaded onto a Varian Mega Bond Elut column. Elution with 0-10% 2.0M methanolic ammonia solution in DCM gave the product (30 mg, 17%). NMR: 2.2 (s, 6H), 3.4 (s, 2H), 7.2 (m, 3H), 7.4 (m, 2H), 7.6 (m, 4H), 8.2 (s, 1H), 8.6 (s, 1H), 9.5 (s, 1H); MS (MH⁺): 422.3, 424.3.

Examples 38-39

The following compounds were prepared by an analogous method to that described in Example 37, starting from 4-anilino-5-bromo-2-(4-iodoanilino)pyrimidine (Method 12) and the appropriate alkyne (commercially available or obtained as described in PCT Int. Appl. WO 9425459):



Ex	R	NMR	MS (MH ⁺)
38	MeNHCH ₂	2.3 (s, 3H), 3.5 (s, 2H), 7.2 (m, 3H), 7.4 (m, 2H), 7.6 (m, 4H), 8.2 (s, 1H), 8.6 (s, 1H), 9.5 (s, 1H)	408.3, 410.3
39		1.3 (m, 1H), 1.6 (m, 1H), 1.8 (m, 4H), 2.6 (m, 3H), 2.8 (d, 1H), 3.0 (s, 1H), 5.5 (s, 1H), 7.2 (m, 3H), 7.4 (m, 2H), 7.6 (m, 4H), 8.2 (s, 1H), 8.6 (s, 1H), 9.5 (s, 1H)	490.1, 492.1

Example 40**4-Anilino-5-bromo-2-[4-(3-amino-1-propynyl)anilino]pyrimidine**

Trifluoroacetic acid (0.25 ml) was added to a solution of 4-anilino-5-bromo-2-{4-[3-(*t*-butoxycarbonylamino)-1-propynyl]anilino}pyrimidine (Method 25; 30 mg, 0.06 mmol) in DCM (1 ml). The solution was left to stand for 3 hours and volatile material was removed by evaporation. The residue was triturated with diethyl ether to give the product as a trifluoroacetate salt (25 mg, 81%). NMR: 4.0 (m, 2H), 7.2 (m, 2H), 7.4 (m, 2H), 7.5-7.7 (m, 4H), 7.8 (m, 1H), 8.2 (br s, 2H), 8.7 (s, 1H), 9.6 (s, 1H); MS (MH⁺): 394.3, 396.3.

10

Example 41**4-Anilino-5-bromo-2-[4-(piperidin-4-yl)methoxyanilino]pyrimidine**

Using an analogous method to that described in Example 40, but starting from 4-anilino-5-bromo-2-{4-[1-(*t*-butoxycarbonyl)piperidin-4-yl]methoxyanilino}pyrimidine (Method 26), the product was obtained. NMR: 1.4-1.6 (m, 2H), 1.8-2.0 (m, 3H), 2.8-3.0 (m, 2H), 3.2-3.3 (m, 2H), 3.8 (d, 2H), 6.8 (d, 2H), 7.25 (t, 1H), 7.3-7.4 (m, 4H), 7.55 (d, 2H), 8.35 (s, 1H), 8.6-9.0 (br d, 1H), 9.0-9.2 (br s, 1H), 9.5 (br s, 1H); MS (MH⁺): 453.9, 455.9.

Preparation of Starting Materials:

The starting materials for the Examples above are either commercially available or are readily prepared by standard methods from known materials. For example, the following reactions are an illustration, but not a limitation, of some of the starting materials used in the above reactions.


20

Method 1**4-Anilino-5-bromo-2-chloropyrimidine**

A solution of 5-bromo-2,4-dichloropyrimidine (6.84 g, 30.0 mmol), aniline (2.79 g, 30.0 mmol) and *N,N*-diisopropylethylamine (3.87 g, 30.0 mmol) in *n*-butanol (75 ml) was heated under reflux for 4 hours. Volatile material was removed by evaporation and the residue was dissolved in DCM (100 ml). The solution was washed with water (3 x 100 ml) and saturated brine (100 ml) and dried. Volatile material was removed by evaporation and the residue was purified by column chromatography, eluting with 15% ethyl acetate/isohexane, to give the product as an oil which solidified on standing (5.12 g, 60%). NMR: 7.1 (t, 1H), 7.4 (t, 2H), 7.55 (d, 2H), 8.4 (s, 1H), 9.2 (br s, 1H); MS (MH⁺): 284, 286, 288.

Methods 2-7

The following intermediates were prepared by an analogous method to that described in Method 1, using the appropriate substituted aniline or aminopyridine and 5-bromo-2,4-dichloropyrimidine or 2,4,5-trichloropyrimidine (Method 8):



Method	X	R ¹	R ²	R ³	MS (MH ⁺)
2	C.CN	Cl	H	H	265.1, 267.1, 269.1
3	CH	Br	H	OMe	314, 316
4 ¹	CH	Br	H	F	
5	CH	Br	Me	H	298, 300, 302
6	N	Br	Me	H	299, 301
7	CH	Br	H	Br	360.0, 362.0, 364.0, 366.0 (MH)

¹ NMR: 7.22 (m, 2H), 7.55 (m, 2H), 8.42 (s, 1H), 9.32 (s, 1H)

Method 8**2,4,5-Trichloropyrimidine**


5-Chlorouracil (10.0 g, 68.5 mmol) was dissolved in phosphorus oxychloride (60 ml) and phosphorus pentachloride (16.0 g, 77.0 mmol) was added. The mixture was heated under
5 reflux for 16 hours, left to cool and then poured slowly into water (200 ml) with vigorous stirring. The mixture was stirred for 1.5 hours and then ethyl acetate (250 ml) was added. The organic layer was separated and the aqueous layer was extracted with a further portion of ethyl acetate (250 ml). The combined extracts were washed with saturated sodium bicarbonate (200 ml) and saturated sodium chloride (200 ml), and then dried. Volatile material was
10 removed by evaporation and the residue was purified by column chromatography, eluting with DCM, to give the product as a yellow liquid (6.37 g, 51%). NMR (CDCl₃): 8.62 (s, 1H); MS (MH⁺): 182, 184, 186.

Method 9**4-Anilino-5-bromo-2-(4-hydroxyanilino)pyrimidine**

4-Aminophenol (0.73 g, 7.8 mmol) and concentrated hydrochloric acid (1.30 ml, 7.1 mmol) were added to 4-anilino-5-bromo-2-chloropyrimidine (Method 1; 3.0 g, 7.1 mmol) in *n*-butanol (30 ml), and the mixture was heated at 100°C for 12 hours. The solid which precipitated out on cooling was filtered off and washed with *n*-butanol and diethyl ether to
20 give the product (0.80 g, 32%). MS (MH⁺): 357, 359.

Methods 10-12

The following intermediates were prepared by an analogous method to that described in Method 9, starting from 4-anilino-5-bromo-2-chloropyrimidine (Method 1) and the
25 appropriate substituted aniline:



Method	R	MS (MH ⁺)
10	3-OH	357, 359
11	4-CH ₂ CH ₂ OH	383.3, 385.3 (MH ⁺)
12	4-I	467.2, 469.2

Method 134-(4-Isopropylpiperazino)carbomethoxyaniline


5 A solution of 4-[(4-isopropylpiperazino)carbomethoxy]nitrobenzene (Method 14, 830 mg, 2.70 mmol) in ethanol (25 ml) was catalytically hydrogenated over 10% palladium-on-carbon (60 mg) for 2 hours. The catalyst was removed by filtration through diatomaceous earth and the filtrate was concentrated to a volume of 5 ml. Ethereal hydrogen chloride (1.0M, 3 ml) was added. and the precipitated solid was collected by filtration to give the product as a
 10 hydrochloride salt (613 mg, 82%). NMR: 0.9 (d, 6H), 2.4 (m, 4H), 2.7 (m, 1H), 3.4 (m, 2H), 4.6 (m, 4H), 6.4(d, 2H), 6.6 (d, 2H); MS (MH⁺): 277.9.

Method 144-[(4-Isopropylpiperazino)carbomethoxy]nitrobenzene

15 1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (2.14 g, 11.0 mmol) was added to a solution of 4-nitrophenoxyacetic acid (obtained as described in J. Med. Chem., 1984, 27, 967-78; 2.0 g, 10.0 mmol), 4-isopropylpiperazine (2.56 g, 20.0 mmol) and 1-hydroxybenzotriazole (2.06 g, 15.0 mmol) in DMF (50 ml) at 0°C. The mixture was stirred for 16 hours and volatile material was removed by evaporation. Water (50 ml) was added and
 20 the mixture was extracted with ethyl acetate (3 x 100 ml). The extracts were dried and concentrated by evaporation to give the product as a yellow solid (600 mg, 22%). NMR: 1.0 (d, 6H), 2.4 (m, 4H), 2.7 (m, 1H), 3.4 (m, 4H), 5.0 (s, 2H), 7.1 (d, 2H), 8.2 (d, 2H); MS (MH⁺): 307.9.

25 Methods 15-17

The following intermediates were prepared by an analogous method to that described in Method 13, starting from the appropriate substituted nitrobenzene (Methods 18-20):



Method	R	MS (MH^+)
15	1-methylpiperidin-4-yl	207.2
16	(1-methylpiperidin-2-yl)methyl	221.2
17	1-methylpiperidin-3-yl	207.2

Method 18

4-(1-Methylpiperidin-4-yloxy)nitrobenzene

5 Triphenylphosphine (7.9 g, 30.0 mmol) was added to a stirred solution of 4-nitrophenol (1.39 g, 10.0 mmol) in DCM (100 ml) and the solution was stirred for 30 minutes. A solution of 4-hydroxy-1-methylpiperidine (1.15 g, 11.0 mmol) in DCM (5 ml) was added and the solution was stirred for 2 minutes. Diethyl azodicarboxylate (4.9 ml, 30.0 mmol) was added dropwise and the mixture was stirred for 4 hours. Volatile material was removed by

10 evaporation and the residue was dissolved in ethyl acetate (200 ml). The solution was washed with water (2 x 100 ml) and then extracted with 2M hydrochloric acid (2 x 50 ml). The combined acidic extracts were washed with ether (2 x 100 ml) and then basified by addition of 0.88 ammonia solution. The basified solution was extracted with ether (2 x 100 ml) and the extracts were washed with water (2 x 100 ml) and saturated sodium chloride (100 ml) and

15 dried. Volatile material was removed by evaporation and a saturated solution of hydrogen chloride in methanol was added to the residue. Volatile material was removed by evaporation and the residue was recrystallized from a mixture of ethanol and ether to give the product as a hydrochloride salt (350 mg). NMR (373 K): 2.0-2.1 (m, 2H), 2.2-2.3 (m, 2H), 2.75 (s, 3H), 2.8-3.0 (m, 2H), 3.2-3.4 (m, 2H), 4.9 (br s, 1H), 7.2 (d, 2H), 8.2 (d, 2H); MS (MH^+): 237.

20

Method 19

4-[(1-Methylpiperidin-2-yl)methoxy]nitrobenzene

Sodium hydride (60% dispersion in oil; 400 mg, 10.0 mmol) was added to a solution of 2-hydroxymethyl-1-methylpiperidine (1.29 g, 10.0 mmol) in DMF (20 ml) and the mixture

was stirred for 2 hours. 4-Fluoronitrobenzene (1.4 g, 10.0 mmol) was added and the mixture was heated at 80°C for 17 hours. The mixture was poured into water (100 ml) and extracted with ethyl acetate (2 x 100 ml). The extracts were washed with water (2 x 100 ml) and then extracted with 2M hydrochloric acid (2 x 50 ml). The combined acidic extracts were washed with ether (2 x 100 ml) and then basified by addition of 0.88 ammonia solution. The basified solution was extracted with ether (2 x 100 ml) and the extracts were washed with water (2 x 100 ml) and saturated sodium chloride (100 ml) and dried. Volatile material was removed by evaporation and a saturated solution of hydrogen chloride in methanol was added to the residue. Evaporation gave the hydrochloride salt of the product as an oil (2.4 g). NMR (asterisk denotes conformeric form): 1.4-1.6 (m, 1H), 1.6-1.9 (m, 4H), 1.9-2.0 (m, 1H), 2.75 (s, 3H)*, 2.8 (s, 3H)*, 3.0-3.2 (m, 2H)*, 3.3-3.4 (m, 2H)*, 3.4-3.6 (m, 1H)*, 3.7-3.9 (m, 1H)*, 4.4 (m, 2H), 7.2 (d, 2H), 8.2 (d, 2H), 10.6-10.8 (br s, 1H)*. 11.0-11.1 (br s, 1H)*; MS (MH⁺): 251.2.


15 Method 20

4-(1-Methylpiperidin-3-yloxy)nitrobenzene

Using an analogous procedure to that described in Method 18, but starting from 4-nitrophenol and 3-hydroxy-1-methylpiperidine, the product was obtained. MS (MH⁺): 237.

20 Methods 21-22

The following intermediates were prepared by an analogous method to that described in Method 13, starting from the appropriate nitrobenzene (Methods 23-24):



Method	R	MS (MH ⁺)
21	i-PrNH	194
22	piperidino	220

Method 23**4-[2-(Isopropylamino)ethylamino]nitrobenzene**

N-Isopropylethylenediamine (4.87 ml, 39.0 mmol) and potassium carbonate (6.37 g, 46.0 mmol) were added to a solution of 4-fluoronitrobenzene (5.0 g, 35.0 mmol) in DMF (50 ml) and the mixture was heated at 70°C for 3 hours under a nitrogen atmosphere. Insoluble material was removed by filtration and the filtrate was concentrated. The residue was dissolved in ethyl acetate (300 ml) and the solution was washed with water (3 x 100 ml) and saturated sodium chloride (50 ml) and dried. The solvent was removed by evaporation to give the product as an orange oil which crystallised on standing (7.55 g, 95%). NMR: 1.0 (d, 6H), 1.7 (m, 1H), 2.7 (m, 3H), 3.2 (m, 1H), 6.6 (m, 2H), 7.1 (m, 1H), 8.0 (m, 2H); MS (MH⁺): 224.

Method 24**4-[2-(Piperidino)ethylamino]nitrobenzene**

Using an analogous procedure to that described in Method 23, but starting from 4-fluoronitrobenzene and 1-(2-aminoethyl)piperidine, the product was obtained. NMR: 1.3 (m, 2H), 1.5 (m, 4H), 2.3 (m, 4H), 2.4 (t, 2H), 3.2 (m, 2H), 6.6 (d, 2H), 7.1 (m, 1H), 8.0 (d, 2H); MS (MH⁺): 250.

Method 25**4-Anilino-5-bromo-2-{4-[3-(*t*-butoxycarbonylamino)-1-propynyl]anilino}pyrimidine**

Using an analogous procedure to that described in Example 37, starting from 4-anilino-5-bromo-2-(4-iodoanilino)pyrimidine (Method 12) and 3-(*t*-butoxycarbonylamino)propyne, the product was obtained. NMR: 1.4 (s, 9H), 3.9 (d, 2H), 7.1-7.3 (m, 4H), 7.4 (m, 2H), 7.6 (m, 4H), 8.2 (s, 1H), 8.6 (s, 1H), 9.5 (s, 1H); MS (MH⁺): 494.3, 496.3.

Method 26**4-Anilino-5-bromo-2-{4-[1-(*t*-butoxycarbonyl)piperidin-4-yl]methoxyanilino}pyrimidine**

Using an analogous procedure to that described in Example 24, starting from 4-anilino-5-bromo-2-(4-hydroxyanilino)pyrimidine (Method 9) and 1-(*t*-butoxycarbonyl)-4-(4-toluenesulphonyloxy)methylpiperidine (obtained as described in PCT Int. Appl. WO 9427965), the product was obtained and was used without characterisation in the next stage.

The following illustrate representative pharmaceutical dosage forms containing the compound of formula (I), or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof (hereafter compound X), for therapeutic or prophylactic use in humans:-

5

(a): Tablet I	mg/tablet
Compound X	100
Lactose Ph.Eur	182.75
Croscarmellose sodium	12.0
Maize starch paste (5% w/v paste)	2.25
Magnesium stearate	3.0

(b): Tablet II	mg/tablet
Compound X	50
Lactose Ph.Eur	223.75
Croscarmellose sodium	6.0
Maize starch	15.0
Polyvinylpyrrolidone (5% w/v paste)	2.25
Magnesium stearate	3.0

(c): Tablet III	mg/tablet
Compound X	1.0
Lactose Ph.Eur	93.25
Croscarmellose sodium	4.0
Maize starch paste (5% w/v paste)	0.75
Magnesium stearate	1.0

(d): Capsule	mg/capsule
Compound X	10
Lactose Ph.Eur	488.5
Magnesium stearate	1.5

(e): Injection I	(50 mg/ml)
Compound X	5.0% w/v
1M Sodium hydroxide solution	15.0% v/v
0.1M Hydrochloric acid	(to adjust pH to 7.6)
Polyethylene glycol 400	4.5% w/v
Water for injection	to 100%

(f): Injection II	10 mg/ml
Compound X	1.0% w/v
Sodium phosphate BP	3.6% w/v
0.1M Sodium hydroxide solution	15.0% v/v
Water for injection	to 100%

(g): Injection III	(1mg/ml, buffered to pH6)
Compound X	0.1% w/v
Sodium phosphate BP	2.26% w/v
Citric acid	0.38% w/v
Polyethylene glycol 400	3.5% w/v
Water for injection	to 100%


5

Note

The above formulations may be obtained by conventional procedures well known in the pharmaceutical art. The tablets (a)-(c) may be enteric coated by conventional means, for example to provide a coating of cellulose acetate phthalate.

Claims

1. A pyrimidine derivative of the formula (I):



(I)

wherein:

- Q₁ and Q₂ are independently selected from aryl or carbon linked heteroaryl; and one of Q₁ and Q₂ or both of Q₁ and Q₂ is substituted on a ring carbon by one substituent selected from *N*-(C₁₋₂alkyl)amino, *N,N*-di-(C₁₋₂alkyl)amino, phenyl, heterocyclic group, phenoxy, heterocyclic group-O-, substituted C₁₋₂alkyl, substituted C₁₋₂alkoxy, substituted C₁₋₂alkoxycarbonyl, substituted *N*-(C₁₋₂alkyl)amino, substituted C₁₋₂alkoxyC₁₋₂alkyl, substituted C₂₋₄alkenyl and substituted C₂₋₄alkynyl; wherein said substituents for C₁₋₂alkyl, C₁₋₂alkoxy, C₁₋₂alkoxycarbonyl, *N*-(C₁₋₂alkyl)amino, C₁₋₂alkoxyC₁₋₂alkyl, C₂₋₄alkenyl and C₂₋₄alkynyl are selected from halo, hydroxy, mercapto, nitro, formyl, formamido, carboxy, cyano, amino, ureido, carbamoyl, sulphamoyl, C₁₋₄alkanoyl, C₁₋₄alkoxycarbonyl, phenyl, heterocyclic group, benzoyl, heterocyclic group-C(O)-, C₁₋₄alkylS(O)_a, wherein a is 0 to 2, *N'*-(C₁₋₄alkyl)ureido, *N',N'*-di-(C₁₋₄alkyl)ureido, *N'*-(C₁₋₄alkyl)-*N*-(C₁₋₄alkyl)ureido, *N',N'*-di-(C₁₋₄alkyl)-*N*-(C₁₋₄alkyl)ureido, *N*-C₁₋₄alkylamino, *N,N*-di-(C₁₋₄alkyl)amino, *N*-(C₁₋₄alkyl)sulphamoyl, *N,N*-di-(C₁₋₄alkyl)sulphamoyl, *N*-C₁₋₄alkylcarbamoyl, *N,N*-di-(C₁₋₄alkyl)carbamoyl and C₁₋₄alkanoylamino; wherein any phenyl, benzyl, benzoyl or heterocyclic group is optionally substituted on a ring carbon by one or more groups selected from R^a; and wherein if any heterocyclic group contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R^b;
- G is -O- or -NR²-;
- R² is selected from hydrogen, C₁₋₆alkyl, C₃₋₆alkenyl and C₃₋₆alkynyl; wherein said C₁₋₆alkyl, C₃₋₆alkenyl and C₃₋₆alkynyl are optionally substituted by one or more groups selected from R^c;

R^1 is selected from hydrogen, halo, hydroxy, nitro, amino, *N*-(C_{1-3} alkyl)amino, *N,N*-di-(C_{1-3} alkyl)amino, cyano, trifluoromethyl, trichloromethyl, C_{1-3} alkyl [optionally substituted by 1 or 2 substituents independently selected from halo, cyano, amino, *N*-(C_{1-3} alkyl)amino, *N,N*-di-(C_{1-3} alkyl)amino, hydroxy and trifluoromethyl], C_{3-5} alkenyl

5 [optionally substituted by up to three halo substituents, or by one trifluoromethyl substituent], C_{3-5} alkynyl, C_{1-3} alkoxy, mercapto, C_{1-3} alkylsulphanyl, carboxy and C_{1-3} alkoxycarbonyl;

Q_1 is optionally substituted on a ring carbon by one to four substituents independently selected from halo, mercapto, nitro, formyl, formamido, carboxy, cyano, amino, ureido, carbamoyl, sulphamoyl, C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl [wherein said C_{1-4} alkyl, C_{2-4} alkenyl

10 and C_{2-4} alkynyl are optionally substituted by one or more groups selected from R^d], C_{1-4} alkanoyl, C_{1-4} alkoxycarbonyl, heterocyclic group, C_{1-4} alkylS(O)_a wherein a is 0 to 2 [optionally substituted by hydroxy], *N*-(C_{1-4} alkyl)ureido, *N',N'*-di-(C_{1-4} alkyl)ureido, *N*-(C_{1-4} alkyl)-*N*-(C_{1-4} alkyl)ureido, *N',N'*-di-(C_{1-4} alkyl)-*N*-(C_{1-4} alkyl)ureido, *N*- C_{1-4} alkylamino, *N,N*-di-(C_{1-4} alkyl)amino, *N*-(C_{1-4} alkyl)sulphamoyl, *N,N*-di-(C_{1-4} alkyl)sulphamoyl, 15 *N*- C_{1-4} alkylcarbamoyl, *N,N*-di-(C_{1-4} alkyl)carbamoyl and C_{1-4} alkanoylamino;

and also independently, or in addition to, the above substituents, Q_1 may be optionally substituted by one to two substituents independently selected from aryl, C_{3-8} cycloalkyl and a heterocyclic group; wherein said aryl, C_{3-8} cycloalkyl or heterocyclic group may be optionally substituted on a ring carbon by one or more groups selected from R^e ; and wherein if said

20 heterocyclic group contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R^f ;

Q_2 is optionally substituted on a ring carbon by one to four substituents independently selected from halo, hydroxy, mercapto, nitro, formyl, formamido, carboxy, cyano, amino, ureido, carbamoyl, sulphamoyl, C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, C_{1-4} alkoxy [wherein said 25 C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl and C_{1-4} alkoxy are optionally substituted by one or more groups selected from R^g], C_{1-4} alkanoyl, C_{1-4} alkoxycarbonyl, heterocyclic group, C_{1-4} alkylS(O)_a wherein a is 0 to 2 [optionally substituted by hydroxy], *N*-(C_{1-4} alkyl)ureido,

N',N'-di-(C_{1-4} alkyl)ureido, *N*-(C_{1-4} alkyl)-*N*-(C_{1-4} alkyl)ureido,

N',N'-di-(C_{1-4} alkyl)-*N*-(C_{1-4} alkyl)ureido, *N*- C_{1-4} alkylamino, *N,N*-di-(C_{1-4} alkyl)amino,

30 *N*-(C_{1-4} alkyl)sulphamoyl, *N,N*-di-(C_{1-4} alkyl)sulphamoyl, *N*- C_{1-4} alkylcarbamoyl,

N,N-di-(C_{1-4} alkyl)carbamoyl, C_{2-4} alkenyloxy, C_{2-4} alkynyloxy, C_{1-4} alkanoylamino;

and also independently, or in addition to, the above substituents, Q_2 may be optionally substituted by one to two substituents independently selected from aryl, C_{3-8} cycloalkyl or a heterocyclic group; wherein said aryl, C_{3-8} cycloalkyl or heterocyclic group may be optionally substituted on a ring carbon by one or more groups selected from R^h ; and wherein if said
 5 heterocyclic group contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R^i ;

R^c , R^d and R^e are independently selected from hydroxy, halo, amino, cyano, formyl, formamido, carboxy, nitro, mercapto, carbamoyl, sulphamoyl, N - C_{1-4} alkylamino, N,N -di- $(C_{1-4}$ alkyl)amino, C_{1-4} alkanoyl, C_{1-4} alkanoyloxy, C_{1-4} alkoxy, C_{1-4} alkoxycarbonyl,
 10 N - C_{1-4} alkylcarbamoyl, N,N -di- $(C_{1-4}$ alkyl)carbamoyl, C_{1-4} alkanoylamino, C_{1-4} alkylS(O)_a wherein a is 0 to 2, C_{1-4} alkylsulphonylamino, N -(C_{1-4} alkyl)sulphamoyl, N -(C_{1-4} alkyl)₂sulphamoyl, N -(C_{1-4} alkyl)carbamoyl, N -(C_{1-4} alkyl)₂carbamoyl, phenyl, phenylthio, phenoxy, C_{3-8} cycloalkyl and a heterocyclic group; wherein said phenyl, phenylthio, phenoxy, C_{3-8} cycloalkyl or heterocyclic group may be optionally substituted on a
 15 ring carbon by one or more groups selected from R^j ; and wherein if said heterocyclic group contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R^k ;

R^a , R^c , R^h and R^j are independently selected from hydroxy, halo, amino, cyano, formyl, formamido, carboxy, nitro, mercapto, carbamoyl, sulphamoyl, C_{1-4} alkyl [optionally
 20 substituted by one or more groups selected from halo, cyano, amino, N - C_{1-4} alkylamino, N,N -di- $(C_{1-4}$ alkyl)amino or hydroxy], C_{2-4} alkenyl [optionally substituted by one or more groups selected from halo], C_{2-4} alkynyl, N - C_{1-4} alkylamino, N,N -di- $(C_{1-4}$ alkyl)amino, C_{1-4} alkanoyl, C_{1-4} alkanoyloxy, C_{1-4} alkoxy [optionally substituted by one or more groups selected from halo], C_{1-4} alkoxycarbonyl, N - C_{1-4} alkylcarbamoyl, N,N -di- $(C_{1-4}$ alkyl)carbamoyl,
 25 C_{1-4} alkanoylamino, C_{1-4} alkylS(O)_a wherein a is 0 to 2, C_{1-4} alkylsulphonylamino, N -(C_{1-4} alkyl)sulphamoyl, N -(C_{1-4} alkyl)₂sulphamoyl, phenyl, C_{3-8} cycloalkyl and a heterocyclic group; and

R^b , R^f , R^i and R^k are independently selected from C_{1-4} alkyl, C_{1-4} alkanoyl, C_{1-4} alkylsulphonyl, carbamoyl, N -(C_{1-4} alkyl)carbamoyl, N,N -(C_{1-4} alkyl)carbamoyl, benzyl,
 30 benzyloxycarbonyl, benzoyl and phenylsulphonyl;
 or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof.

2. A pyrimidine derivative as claimed in claim 1 wherein Q₁ is phenyl or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof.

3. A pyrimidine derivative as claimed in either of claims 1 or 2 wherein Q₂ is phenyl or
5 pyridyl or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof.

4. A pyrimidine derivative as claimed in any one of claims 1 to 3 wherein one of Q₁ and Q₂ or both of Q₁ and Q₂ is substituted on a ring carbon by one substituent selected from dimethylamino, 4-methylpiperazino, aminomethyl, 2-hydroxyethoxymethyl, succinimid-1-
10 ylmethyl, 2-pyrrolidin-1-ylethyl, 2-aminoethyl, piperid-4-yloxy, 1-methylpiperid-4-yloxy, 1-methylpiperid-3-yloxy, carboxymethoxy, 1-methylpiperid-2-ylmethoxy, 1-methylpiperid-3-ylmethoxy, piperid-4-ylmethoxy, 4-isopropylpiperazinocarbonylmethoxy, 2-phthalimid-1-ylethoxy, 2-morpholinoethoxy, 2-dimethylaminoethoxy, 2-diethylaminoethoxy, 2-(4-methylpiperazino)ethoxy, 2-imidazol-1-ylethoxy, 2-pyrrolidin-1-ylethoxy, 2-aminoethynyl, 2-
15 dimethylaminoethynyl, 2-methylaminoethynyl, 2-(3-hydroxyquinuclidin-3-yl)ethynyl, 2-morpholinoethoxymethyl, 2-diethylaminoethoxymethyl, 2-pyrrolidin-1-ylethoxymethyl, 2-(4-methylpiperazino)ethoxymethyl, 2-diethylaminoethoxycarbonyl, 2-piperidinoethylamino or 2-isopropylaminoethylamino or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof.

20

5. A pyrimidine derivative as claimed in any one of claims 1 to 4 wherein Q₁ is substituted in the para- or meta- position relative to the -NH- or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof.


25 6. A pyrimidine derivative as claimed in any one of claims 1 to 5 wherein G is -NH- or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof.

7. A pyrimidine derivative as claimed in any one of claims 1 to 6 wherein R¹ is hydrogen, chloro or bromo or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester
30 thereof.

8. A pyrimidine derivative as claimed in any one of claims 1 to 7 wherein Q₂ is


unsubstituted or substituted by one group selected from fluoro, bromo, methyl, methoxy and cyano or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof.

9. A pyrimidine derivative as claimed in any one of claims 1 to 8 selected from:
- 5 4-anilino-5-bromo-2-[4-(2-dimethylaminoethoxy)anilino]pyrimidine;
 4-anilino-5-bromo-2-[4-(carboxymethoxy)anilino]pyrimidine;
 4-anilino-5-bromo-2-[4-(1-methylpiperid-4-yloxy)anilino]pyrimidine;
 4-(6-methylpyrid-2-yl)-5-bromo-2-[4-(2-piperid-1-ylethylamino)anilino]pyrimidine;
 4-anilino-5-bromo-2-[4-(2-isopropylaminoethylamino)anilino]pyrimidine; or
- 10 4-anilino-5-bromo-2-[4-(3-methylamino-1-propynyl)anilino]pyrimidine;
 or pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof.
10. A process for preparing a pyrimidine derivative as claimed in any one of claims 1 to 9 selected from:
- 15 a) for compounds of formula (I) where G is $-NR^2-$; reacting a pyrimidine of formula (II):



(II)

wherein L is a displaceable group as defined below, with a compound of formula (III):




(III)

20


where G is $-NR^2-$;

b) reaction of a pyrimidine of formula (IV):



(IV)

wherein L is a displaceable group as defined below, with a compound of formula (V):



(V)

and thereafter if necessary:

- 5 i) converting a compound of the formula (I) into another compound of the formula (I);
- ii) removing any protecting groups;
- iii) forming a pharmaceutically acceptable salt or *in vivo* hydrolysable ester.

11. A pharmaceutical composition which comprises a pyrimidine derivative of the formula
10 (I), or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, as claimed in any one of claims 1 to 9, in association with a pharmaceutically acceptable diluent or carrier.

12. A pyrimidine derivative of the formula (I), or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, as claimed in any one of claims 1 to 9, for use in a method of
15 prophylactic or therapeutic treatment of a warm-blooded animal, such as man.

13. A pyrimidine derivative of the formula (I), or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, as claimed in any one of claims 1 to 9, for use as a
medicament.

20

14. The use of a pyrimidine derivative of the formula (I), or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, as claimed in any one of claims 1 to 9, in the manufacture of a medicament for use in the production of an anti-cancer, cell cycle inhibitory (anti-cell-proliferation) effect and/or a FAK inhibitory (anti-cell migration and/or apoptosis
25 inducing) effect in a warm-blooded animal such as man.

15. A method for producing an anti-cancer, cell cycle inhibitory (anti-cell-proliferation) effect and/or a FAK inhibitory (anti-cell migration and/or apoptosis inducing) effect in a warm-blooded animal, such as man, in need of such treatment which comprises administering

to said animal an effective amount of a pyrimidine derivative as claimed in any one of claims 1 to 9, or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 01/00829

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C07D239/48 C07D403/12

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal, PAJ, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 95 09852 A (CIBA GEIGY AG) 13 April 1995 (1995-04-13) claims; examples ---	4-14
Y	EP 0 564 409 A (CIBA GEIGY AG) 6 October 1993 (1993-10-06) claims; examples ---	4-14
P,Y	WO 00 12485 A (BREault GLORIA ANNE ; PEASE JANET ELIZABETH (GB); ZENECA LTD (GB)) 9 March 2000 (2000-03-09) claims; examples ---	4-14
P,Y	WO 00 39101 A (BREault GLORIA ANNE ; PEASE JANET ELIZABETH (GB); ASTRAZENECA UK LT) 6 July 2000 (2000-07-06) claims; examples --- -/--	4-14

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *Z* document member of the same patent family

Date of the actual completion of the international search

1 June 2001

Date of mailing of the international search report

12/06/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Menegaki, F

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/GB 01/00829

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,Y	<p>WO 00 53595 A (BREAUULT GLORIA ANNE ;JAMES STEWART RUSSELL (GB); PEASE JANE ELIZAB)</p> <p>14 September 2000 (2000-09-14)</p> <p>claims; examples</p> <p>-----</p>	4-14

INTERNATIONAL SEARCH REPORT

International application No.

PCT/ GB/ 01/ 00829

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

SEE ANNEXE

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 1-3

Present claims 1-3 relate to an extremely large number of possible compounds. Support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT is to be found, however, for only a very small proportion of the compounds claimed. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Consequently, the search has been carried out for those parts of the claims which appear to be supported and disclosed, namely those parts relating to the compounds of formula (I) of Claim 1 as further specified in claims 2, 3 and 4.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

Int. tional Application No

PCT/GB 01/00829

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9509852	A	13-04-1995	AU 693804 B	09-07-1998
			AU 7697594 A	01-05-1995
			CA 2148477 A	13-04-1995
			EP 0672040 A	20-09-1995
			JP 8504834 T	28-05-1996
			US 5521184 A	28-05-1996
			US 5543520 A	06-08-1996
EP 0564409	A	06-10-1993	AT 188964 T	15-02-2000
			AU 3569493 A	07-10-1993
			BR 1100739 A	06-06-2000
			CA 2093203 A	04-10-1993
			CN 1077713 A,B	27-10-1993
			CZ 9300560 A	16-02-1994
			DE 59309931 D	24-02-2000
			DK 564409 T	19-06-2000
			ES 2142857 T	01-05-2000
			FI 931458 A	04-10-1993
			GR 3032927 T	31-07-2000
			HU 64050 A	29-11-1993
			IL 105264 A	11-04-1999
			JP 2706682 B	28-01-1998
			JP 6087834 A	29-03-1994
			MX 9301929 A	29-07-1994
			NO 302473 B	09-03-1998
			NZ 247299 A	26-07-1995
			PT 564409 T	30-06-2000
			RU 2125992 C	10-02-1999
			SG 43859 A	14-11-1997
			SK 28093 A	06-04-1994
			US 5521184 A	28-05-1996
			ZA 9302397 A	04-10-1993
WO 0012485	A	09-03-2000	AU 5438299 A	21-03-2000
WO 0039101	A	06-07-2000	AU 1874300 A	31-07-2000
WO 0053595	A	14-09-2000	AU 2818700 A	28-09-2000

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☒ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☒ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.